<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta name="generator" content=
"HTML Tidy for HTML5 for Mac OS X version 5.4.0" />
<title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif">
<p style="margin-top: 0; margin-bottom: 0; text-align: center">
&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0; text-align: center"></p>
<!-- Field: Rule-Page -->
<div align="left">
<div style=
"font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin-top: 0; margin-bottom: 0; text-align: center">
&nbsp;</p>
<p style="margin-top: 0; text-align: center; margin-bottom: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>UNITEDSTATES</b></font><br />

<font style=
"font-family: Times New Roman, Times, Serif; font-size: 14pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></font></p>
<p style="margin-top: 0; text-align: center; margin-bottom: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,D.C.
20549</b></font></p>
<p style="margin-top: 0; text-align: center; margin-bottom: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style="margin-top: 0; text-align: center; margin-bottom: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM10-Q</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 12pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font: 12pt Times New Roman, Times, Serif"><b>QUARTERLYREPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE</b></font><br />
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 76.05pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forthe
quarterly period ended March 31, 2018</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OR</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>TRANSITIONREPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE</b></font><br />
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>SECURITIES
EXCHANGE ACT OF 1934</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forthe
transition period from ________ to ________</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font: 10pt Times New Roman, Times, Serif"><b>Commission File
Number: 333-88480</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 24pt"><b>OHRPHARMACEUTICAL,
INC.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Exactname
of registrant as specified in its charter)</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
<td style=
"width: 49%; text-align: center; border-bottom: Black 1pt solid">
<font style="font-size: 10pt"><b>Delaware</b></font></td>
<td style="width: 2%; padding-bottom: 1pt"><b>&nbsp;</b></td>
<td style=
"width: 49%; text-align: center; border-bottom: Black 1pt solid">
<font style="font-size: 10pt"><b>46-5622433</b></font></td>
</tr>
<tr style="vertical-align: top">
<td style="text-align: center"><font style="font-size: 10pt">(State
or other jurisdiction of incorporation or organization)</font></td>
<td>&nbsp;</td>
<td style="text-align: center"><font style=
"font-size: 10pt">(I.R.S. Employer Identification No.)</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>800Third
Avenue, 11th Floor</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NewYork,
NY 10022</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(Addressof
principal executive offices)</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(212)682-8452</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant’
stelephone number, including area code)</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicateby
check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities
ExchangeAct of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports),and (2) has been subject to such filing requirements for
the past 90 days.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&nbsp;☒&nbsp;&nbsp;No&nbsp;☐&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicateby
check mark whether the registrant has submitted electronically and
posted on its corporate Web site, if any, every InteractiveData
File required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (§232.405 of this Chapter) during thepreceding 12
months (or for such shorter period that the registrant was required
to submit and post such files).&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&nbsp;☒&nbsp;&nbsp;No&nbsp;☐&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicateby
check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smallerreporting
company. See the definitions of “large accelerated filer”, 
“accelerated filer” and “smallerreporting company” in Rule 12b-2 of
the Exchange Act.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; border-collapse: collapse; font-size: 10pt">
<tr style="vertical-align: top">
<td style=
"width: 40%; font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
accelerated filer</font></td>
<td style=
"width: 11%; padding-left: 16.6pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">☐</font></td>
<td style=
"width: 24%; font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
filer</font></td>
<td style=
"width: 25%; padding-right: 0.25pt; font-family: Times New Roman,serif; text-align: right; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">☐</font></td>
</tr>
<tr style="vertical-align: top">
<td style=
"font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
<td style=
"padding-left: 10.7pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
<td style=
"font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
<td style=
"font-family: Times New Roman,serif; text-align: right; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
</tr>
<tr style="vertical-align: top">
<td style=
"font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
filer</font></td>
<td style=
"padding-left: 16.6pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">☐</font></td>
<td style=
"font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
reporting company</font></td>
<td style=
"padding-right: 0.25pt; font-family: Times New Roman,serif; text-align: right; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">☒</font></td>
</tr>
<tr style="vertical-align: top">
<td style=
"font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style="font: 10pt Times New Roman, Times, Serif">(Do not
check if smaller reporting company</font>)</td>
<td style=
"padding-left: 10.7pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
<td style=
"font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
<td style=
"font-family: Times New Roman,serif; text-align: right; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
</tr>
<tr style="vertical-align: top">
<td style=
"font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
</td>
<td style=
"padding-left: 10.7pt; font-family: Times New Roman,serif; text-align: center; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></td>
<td style=
"font-family: Times New Roman,serif; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company</font></td>
<td style=
"font-family: Times New Roman,serif; text-align: right; text-indent: 0in">
☐</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ifan
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period forcomplying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicateby
check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act).</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes&nbsp;☐&nbsp;&nbsp;No&nbsp;☒</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicatethe
number of shares outstanding of each of the issuer’s classes of
common stock, as of the latest practicable date: 56,466,428shares
of Common Stock outstanding as of May 15, 2018.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<!-- Field: Rule-Page -->
<div align="left">
<div style=
"font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid; width: 100%">
&nbsp;</div>
</div>
<!-- Field: /Rule-Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<!-- Field: Page; Sequence: 1 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
&nbsp;</p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OHRPHARMACEUTICAL,
INC.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TABLEOF
CONTENTS</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
<td style="vertical-align: top; width: 95%">&nbsp;</td>
<td style="vertical-align: bottom; width: 5%; text-align: right">
<font style="font-size: 10pt">Page</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a001"><font style="font-size: 10pt">PART I
&nbsp;FINANCIAL INFORMATION</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">3</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a002"><font style="font-size: 10pt">Item 1.
Financial Statements (Unaudited)</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">3</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a003"><font style="font-size: 10pt">Item 2.
Management’s Discussion and Analysis of Financial Condition and
Results of Operations</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">10</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a004"><font style="font-size: 10pt">Item 3.
Quantitative and Qualitative Risk</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">14</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a005"><font style="font-size: 10pt">Item 4. Controls
and Procedures</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">14</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a006"><font style="font-size: 10pt">PART II
&nbsp;OTHER INFORMATION</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">14</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a007"><font style="font-size: 10pt">Item 1. Legal
Proceedings</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">14</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a008"><font style="font-size: 10pt">Item 1A Risk
Factors</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">14</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a009"><font style="font-size: 10pt">Item 2.
Unregistered Sales of Equity Securities and Use of
Proceeds</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">27</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a010"><font style="font-size: 10pt">Item 3. Defaults
Upon Senior Securities</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">27</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a011"><font style="font-size: 10pt">Item 4. Mine
Safety Disclosures</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">27</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href="#ohrp10q033118a012">Item
5. Other Information</a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">27</font></td>
</tr>
<tr>
<td style="vertical-align: top">&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style="vertical-align: top"><a href=
"#ohrp10q033118a013"><font style="font-size: 10pt">Item 6.
Exhibits</font></a></td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">27</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td>
<td style="width: 0.75in; text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><a name="ohrp10q033118a001"
id="ohrp10q033118a001"></a>Part I</font></td>
<td style="text-align: justify"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">FINANCIAL
INFORMATION</font></td>
</tr>
</table>
<p style=
"font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0pt"></td>
<td style="width: 0.75in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><a name="ohrp10q033118a002"
id="ohrp10q033118a002"></a>Item 1.</font></td>
<td style="text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
Statements.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
</p>
<table cellspacing="0" cellpadding="0" style=
"width: 100%; border-collapse: collapse; font-size: 10pt">
<tr>
<td style=
"vertical-align: top; width: 96%; padding-left: 8.65pt; text-indent: -8.65pt">
<font style="font-size: 10pt">TABLE OF CONTENTS</font></td>
<td style="width: 1%">&nbsp;</td>
<td style="vertical-align: bottom; width: 3%; text-align: right">
<font style="font-size: 10pt">PAGE</font></td>
</tr>
<tr>
<td style=
"vertical-align: top; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="vertical-align: bottom; text-align: right">&nbsp;</td>
</tr>
<tr>
<td style=
"vertical-align: top; padding-left: 8.65pt; text-indent: -8.65pt">
<a href="#ohrp10q033118b001"><font style=
"font-size: 10pt">Unaudited Consolidated Balance Sheets as of March
31, 2018 and September 30, 2017</font></a></td>
<td>&nbsp;</td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">4</font></td>
</tr>
<tr>
<td style=
"vertical-align: top; padding-left: 8.65pt; text-indent: -8.65pt">
<a href="#ohrp10q033118b002"><font style=
"font-size: 10pt">Unaudited Consolidated Statements of Operations
for the three months and six months ended March 31, 2018 and
2017</font></a></td>
<td>&nbsp;</td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">5</font></td>
</tr>
<tr>
<td style=
"vertical-align: top; padding-left: 8.65pt; text-indent: -8.65pt">
<a href="#ohrp10q033118b003"><font style=
"font-size: 10pt">Unaudited Consolidated Statements of Cash Flows
for the six months ended March 31, 2018 and 2017</font></a></td>
<td>&nbsp;</td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">6</font></td>
</tr>
<tr>
<td style=
"vertical-align: top; padding-left: 8.65pt; text-indent: -8.65pt">
<a href="#ohrp10q033118b004"><font style="font-size: 10pt">Notes to
Unaudited Consolidated Financial Statements</font></a></td>
<td>&nbsp;</td>
<td style="vertical-align: bottom; text-align: right"><font style=
"font-size: 10pt">7</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
&nbsp;</p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
</p>
<!-- Field: Page; Sequence: 3; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OHRPHARMACEUTICAL,
INC.</b></font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
&nbsp;</p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif; text-align: center">
<a name="ohrp10q033118b001" id="ohrp10q033118b001"></a><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ConsolidatedBalance
Sheets</b></font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&nbsp;</b></font></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">&nbsp;</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
<td colspan="2">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
March 31,<br />
2018</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
September 30,<br />
2017</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td colspan="8" style="text-align: center"><u>ASSETS</u></td>
<td style="padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
CURRENT ASSETS</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 74%; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Cash</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">5,215,247</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 10%; text-align: right">12,801,085</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 1pt">
Prepaid expenses and other current assets</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
622,184</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
223,278</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 1pt">
Total Current Assets</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
5,837,431</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
13,024,363</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
EQUIPMENT, net</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
20,448</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
63,757</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
OTHER ASSETS</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Security deposit</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">12,243</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Intangible assets, net</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">13,529,626</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">14,087,602</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 1pt">
Goodwill</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">—
</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
740,912</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 2pt">
TOTAL ASSETS</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
19,387,505</td>
<td style="text-align: left; padding-bottom: 2pt">&nbsp;</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
27,928,877</td>
<td style="text-align: left; padding-bottom: 2pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td colspan="8" style=
"text-decoration: underline; text-align: center">LIABILITIES AND
STOCKHOLDERS’ EQUITY</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
CURRENT LIABILITIES</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Accounts payable and accrued expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">1,444,465</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">4,827,525</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 1pt">
Notes payable</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
287,902</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
106,387</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 1pt">
Total Current Liabilities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
1,732,367</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
4,933,912</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Long-term liabilities</td>
<td>&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">—
</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
150,000</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 1pt">
TOTAL LIABILITIES</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
1,732,367</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
5,083,912</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
STOCKHOLDERS’ EQUITY</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Preferred stock, Series B; 6,000,000 shares authorized, $0.0001 par
value, 0 shares issued and outstanding, respectively</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Common stock; 180,000,000 shares authorized, $0.0001 par value,
56,466,428 and 56,196,428 shares issued and outstanding,
respectively</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,647</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,619</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Additional paid-in capital</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">132,074,223</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">130,927,953</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 1pt">
Accumulated deficit</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(114,424,732</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(108,088,607</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 1pt">
Total Stockholders’ Equity</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
17,655,138</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
22,844,965</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 2pt">
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
19,387,505</td>
<td style="text-align: left; padding-bottom: 2pt">&nbsp;</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
27,928,877</td>
<td style="text-align: left; padding-bottom: 2pt">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Theaccompanying
notes are an integral part of these unaudited consolidated
financial statements.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
</p>
<!-- Field: Page; Sequence: 4; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OHRPHARMACEUTICAL,
INC.&nbsp;&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<a name="ohrp10q033118b002" id="ohrp10q033118b002"></a><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ConsolidatedStatements
of Operations</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)&nbsp;</b></font></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td colspan="2" style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td colspan="2" style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td colspan="2" style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td colspan="2" style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="6" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
For the Three Months Ended<br />
March 31,</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="6" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
For the Six Months Ended<br />
March 31,</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
2018</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
2017</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
2018</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
2017</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
OPERATING EXPENSES</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 52%; font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
General and administrative</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
591,184</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
1,404,061</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
2,101,216</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
3,150,417</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Research and development</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">1,801,946</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">5,993,928</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">4,189,677</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">10,925,072</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Depreciation and amortization</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">278,525</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">291,875</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">563,511</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">590,310</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Loss on impairment of goodwill</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">740,912</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">740,912</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
Gain on settlement of liabilities</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(1,228,805</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
—</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(1,228,805</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
—</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
OPERATING LOSS</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">2,183,762</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">7,689,864</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">6,366,511</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">14,665,799</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
OTHER INCOME (EXPENSE)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Other income (expense)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">(17,814</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">(17,799</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 1pt">
Interest income (expense), net</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
16,809</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(208</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
48,185</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
73</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 1pt">
Total Other Income (Expense)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(1,005</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(208</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
30,386</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
73</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding: 0; text-indent: 0">
LOSS FROM OPERATIONS</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(2,184,767</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(7,690,072</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(6,336,125</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
(14,665,726</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 2pt">
NET LOSS</td>
<td style="font-size: 10pt; padding-bottom: 2pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2pt double">
$</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2pt double">
(2,184,767</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 2pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2pt double">
$</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2pt double">
(7,690,072</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 2pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2pt double">
$</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2pt double">
(6,336,125</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2pt">
)</td>
<td style="font-size: 10pt; padding-bottom: 2pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2pt double">
$</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2pt double">
(14,665,726</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2pt">
)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
BASIC AND DILUTED LOSS PER SHARE (in dollars per share)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">(0.04</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">(0.21</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">(0.11</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">(0.43</td>
<td style="font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
BASIC AND DILUTED</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">56,464,984</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">36,738,396</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">56,332,939</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">34,381,781</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Theaccompanying
notes are an integral part of these unaudited financial
statements.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
</p>
<!-- Field: Page; Sequence: 5; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OHRPHARMACEUTICAL,
INC.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<a name="ohrp10q033118b003" id="ohrp10q033118b003"></a><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ConsolidatedStatements
of Cash Flows</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Unaudited)</b></font></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td colspan="2" style="font-weight: bold; text-align: center">
&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
<td colspan="2" style="font-weight: bold; text-align: center">
&nbsp;</td>
<td style="font-weight: bold">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="6" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For
the Six Months Ended</b></font><br />
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>March
31,</b></font></td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
OPERATING ACTIVITIES</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 76%; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Net loss</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(6,336,125</td>
<td style="width: 1%; text-align: left">)</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(14,665,726</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Adjustments to reconcile net loss to net cash used by operating
activities:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Common stock issued for services</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">145,301</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">633,697</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Stock option expense</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">730,997</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">846,270</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Depreciation</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,535</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">31,060</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Amortization of intangible assets</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">557,976</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">559,250</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Gain on settlement of liabilities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,228,805</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Loss on sale of property and equipment</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">17,814</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Loss on impairment of goodwill</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">740,912</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Changes in operating assets and liabilities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Prepaid expenses and other current assets</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(43,609</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">310,429</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 1pt">
Accounts payable and accrued expenses</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(4,761,865</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
2,386,713</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.5in; text-indent: -8.65pt">Net
Cash Used in Operating Activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(7,714,259</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(9,898,307</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
INVESTING ACTIVITIES</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 1pt">
Purchase of property and equipment</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">—
</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(4,833</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.5in; text-indent: -8.65pt">Net
Cash Provided by/ (Used in) Investing Activities</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(4,833</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
FINANCING ACTIVITIES</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Proceeds for issuance of common stock for cash</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">6,846,483</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Proceeds from warrants exercised for cash</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">270,000</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">118,801</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 1pt">
Repayments of short-term notes payable</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(141,579</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(87,798</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt; padding-bottom: 1pt">
Net Cash Provided by/ (Used in) Financing Activities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
128,421</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
6,877,486</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">NET
CHANGE IN CASH</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(7,585,838</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(3,025,654</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
CASH AT BEGINNING OF PERIOD</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
12,801,085</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
12,546,890</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 2pt">
CASH AT END OF PERIOD</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
5,215,247</td>
<td style="text-align: left; padding-bottom: 2pt">&nbsp;</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
9,521,236</td>
<td style="text-align: left; padding-bottom: 2pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION CASH PAID
FOR:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Interest</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">2,899</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">$</td>
<td style="text-align: right">798</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Income Taxes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="padding-left: 8.65pt; text-indent: -8.65pt">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">NON
CASH FINANCING ACTIVITIES:</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Financing of insurance premiums through issuance of short term
notes</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">323,094</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">261,326</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.375in; text-indent: -8.65pt">
Subscriptions receivable from exercise of warrants</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
The accompanying notes arean integral part of these unaudited
financial statements.</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<br /></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
</p>
<!-- Field: Page; Sequence: 6; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<a name="ohrp10q033118b004" id="ohrp10q033118b004"></a><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Notesto
Unaudited Consolidated Financial Statements&nbsp;</font></p>
<p style=
"font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.5pt; text-align: center; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">March31,
2018</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE1
– BASIS OF PRESENTATION</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Theaccompanying
unaudited consolidated financial statements include the accounts of
Ohr Pharmaceutical, Inc. and its subsidiaries(the “Company”). The
accompanying unaudited consolidated financial statements have been
prepared in accordance withaccounting principles generally accepted
in the United States (“GAAP”) for interim financial information and
withthe instructions to Form 10-Q and Rule 10-01 of Regulation S-X
related to interim period financial statements. Accordingly,
theseconsolidated financial statements do not include certain
information and footnotes required by GAAP for complete financial
statements.However, in the opinion of management, all adjustments
(which include only normal recurring adjustments) necessary to
presentfairly the financial position, results of operations, and
cash flows at March 31, 2018, and for all periods presented
herein,have been made.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Itis
suggested that these unaudited consolidated financial statements be
read in conjunction with the consolidated financial statementsand
notes thereto included in the Company’s Annual Report on Form 10-K
for the fiscal year ended September 30, 2017. Theresults of
operations for the quarterly periods ended March 31, 2018 and 2017
are not necessarily indicative of the operatingresults for the full
years.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE2
– SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND GOING
CONCERN</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Useof
Estimates</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thepreparation
of financial statements in conformity with GAAP requires management
to make estimates and assumptions that affectthe reported amounts
of assets and liabilities at the date of the financial statements
and the reported amounts of revenue andexpenses during the
reporting period. Actual results could differ from those estimates.
Estimates subject to change in the nearterm include impairment (if
any) of long-lived assets.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Impairmentof
Long-Lived Assets</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-livedtangible
assets and definite-lived intangible assets are reviewed for
possible impairment whenever events or changes in
circumstancesindicate that the carrying amount of such assets may
not be recoverable. The Company uses an estimate of undiscounted
future netcash flows of the assets over the remaining useful lives
in determining whether the carrying value of the assets is
recoverable.If the carrying values of the assets exceed the
expected future cash flows of the assets, the Company recognizes an
impairmentloss equal to the difference between the carrying values
of the assets and their estimated fair values. Impairment of
long-livedassets is assessed at the lowest levels for which there
are identifiable cash flows that are independent from other groups
ofassets. The evaluation of long-lived assets requires the Company
to use estimates of future cash flows. However, actual cash
flowsmay differ from the estimated future cash flows used in these
impairment tests. At March 31, 2018, the Company determined thatdue
to the significant drop in the price of the Company’s common stock,
an impairment analysis was required for the intangibleassets and
goodwill. The Company performed the tests and concluded that the
intangible assets were not impaired and the goodwillwas impaired
and wrote off the $740,912 goodwill balance.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>FairValue
of Financial Instruments</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Inaccordance
with ASC 820, the carrying value of cash and cash equivalents,
accounts payable and notes payable approximates fairvalue due to
the short-term maturity of these instruments. ASC 820 clarifies the
definition of fair value, prescribes methodsfor measuring fair
value, and establishes a fair value hierarchy to classify the
inputs used in measuring fair value as follows:</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Level1
- Inputs are unadjusted quoted prices in active markets for
identical assets or liabilities available at the measurement
date.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Level2
- Inputs are unadjusted quoted prices for similar assets and
liabilities in active markets, quoted prices for identical or
similarassets and liabilities in markets that are not active,
inputs other than quoted prices that are observable, and inputs
derivedfrom or corroborated by observable market data.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Level3
- Unobservable inputs, where there is little or no market activity
for the asset or liability. These inputs reflect the
reportingentity’s own beliefs about the assumptions that market
participants would use in pricing the asset or liability, based
onthe best information available in the circumstances.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereare
no assets and liabilities that are measured and recognized at fair
value as of March 31, 2018 and September 30, 2017, on arecurring
basis.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>RecentAccounting
Pronouncements</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany
has implemented all new relevant accounting pronouncements that are
in effect through the date of these financial statements.The
pronouncements did not have any material impact on the financial
statements unless otherwise disclosed, and the Company doesnot
believe that there are any other new accounting pronouncements that
have been issued that might have a material impact onits
consolidated financial position or results of
operations.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>GoingConcern</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Todate,
the Company has no revenue from product sales and management
expects continuing operating losses and negative cash outflowsin
the future. These factors raise substantial doubt about the Company’
s ability to continue as a going concern. The
accompanyingconsolidated financial statements have been prepared on
a going concern basis, which contemplates the realization of assets
andsatisfaction of liabilities in the ordinary course of business.
Management expects to seek additional funds through equity ordebt
financings or through collaboration, licensing transactions or
other sources. The Company may be unable to obtain equityor debt
financings or enter into collaboration or licensing transactions.
The consolidated financial statements do not includeany adjustments
relating to the recoverability and classification of recorded asset
amounts or the amounts and classificationof liabilities that might
result from the outcome of this uncertainty.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
</p>
<!-- Field: Page; Sequence: 7; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE3
– INTANGIBLE ASSETS</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangibleassets
at March 31, 2018 and September 30, 2017:</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<table cellpadding="0" cellspacing="0" align="center" style=
"border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td colspan="2" style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td colspan="2" style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
March 31,<br />
2018</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
September 30,<br />
2017</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 56%; font-size: 10pt; text-align: left">License
Rights</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
17,712,991</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
17,712,991</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
Patent Costs</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">200,000</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">200,000</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">17,912,991</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">17,912,991</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left">Accumulated
Amortization</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">(4,383,365</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">(3,825,389</td>
<td style="font-size: 10pt; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total
Intangible Assets</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">
$</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
13,529,626</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">
$</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
14,087,602</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Duringthe
three month and six month periods ended March 31, 2017 the Company
recognized $276,551, and $559,250, respectively, in
amortizationexpense on the patents and license rights. During the
three month and six month periods ended March 31, 2018 the Company
recognized$275,857, and $557,976, respectively, in amortization
expense on the patents and license rights. The amortization expense
hasbeen included in research and development expense.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE4
– NOTES PAYABLE</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OnFebruary
28, 2017, the Company entered into a premium financing arrangement
for its directors’ and officers’insurance policy in the amount of
$261,326. The financing arrangement bears interest at 7.5% per
annum. The Company hasrepaid the note in full in the amount of
$261,326 of principal, of which $106,387 was paid in the six months
ended March 31,2018. The Company has paid total interest of
$9,067.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OnFebruary
28, 2018, the Company entered into a premium financing arrangement
for its directors’ and officers’ insurancepolicy in the amount of
$323,094. The financing arrangement bears interest at a rate of
7.29% per annum. As of March 31, 2018,the Company had repaid
$35,192 of the loan and had recorded interest of $1,807.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE5
– EQUITY</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>CommonStock
Warrants</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Duringthe
six months ended March 31, 2018, 270,000 shares of common stock
were issued in connection with the exercise of warrants issuedand
sold to various purchasers as part of a registered offering that
closed in April 2017. The warrants were exercised at a priceof
$1.00 per share, and $270,000 in cash was received during the six
months ended March 31, 2018.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Belowis
a table summarizing the warrants issued and outstanding as of March
31, 2018 (“Price” reflects the weighted averageexercise price per
share):</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<table cellpadding="0" cellspacing="0" align="center" style=
"border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
Warrants</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
Price</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 56%; font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
Outstanding at September 30, 2017</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
16,178,110</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 9%; font-size: 10pt; text-align: right">1.23</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
Granted</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Investor warrants</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Stock-based compensation warrants</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">250,000</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">1.00</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
Exercised</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Investor warrants</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">(270,000</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">1.00</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Stock-based compensation warrants</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Forfeited or expired</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Investor warrants</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Stock-based compensation warrants</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">(40,000</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">4.32</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt">
Outstanding at March 31, 2018</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">16,118,110</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">1.22</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 2.5pt">
Exercisable at March 31, 2018</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
16,118,110</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">
$</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
1.22</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Asof
March 31, 2018, the warrants have a weighted average remaining term
of 3.95 years and have no intrinsic value.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<!-- Field: Page; Sequence: 8; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>StockBased
Compensation</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany’
s Consolidated 2016 Stock Plan (“the Plan”) provides for granting
stock options and restricted stockawards to employees, directors
and consultants of the Company. The Company uses the Black-Scholes
pricing model for determiningthe fair value of stock options and
warrants granted as share based compensation.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thefollowing
assumptions were used to calculate the fair value of the Company’s
warrants and options issued during the sixmonth period ended March
31, 2018:</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<table cellpadding="0" cellspacing="0" align="center" style=
"border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
<b>&nbsp;</b></td>
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
<b>&nbsp;</b></td>
<td style=
"border-bottom: Black 1pt solid; font-size: 10pt; text-align: center; vertical-align: bottom">
<b>Warrants</b></td>
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
<b>&nbsp;</b></td>
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
<b>&nbsp;</b></td>
<td colspan="2" style=
"font-size: 10pt; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
<b>Options</b></td>
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
<b>&nbsp;</b></td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt">Expected term</td>
<td style="font-size: 10pt">&nbsp;</td>
<td nowrap="nowrap" style="font-size: 10pt; text-align: right">1.59
to 2 years</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td colspan="2" nowrap="nowrap" style=
"white-space: nowrap; font-size: 10pt; text-align: right">3.25 to 5
years</td>
<td style="font-size: 10pt">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="width: 65%; font-size: 10pt; text-align: left">Expected
volatility</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 15%; font-size: 10pt; text-align: right">
73%-161</td>
<td style="width: 1%; font-size: 10pt; text-align: left">%</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 15%; font-size: 10pt; text-align: right">101</td>
<td style="width: 1%; font-size: 10pt; text-align: left">%</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left">Expected
dividends</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">0</td>
<td style="font-size: 10pt; text-align: left">%</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">0</td>
<td style="font-size: 10pt; text-align: left">%</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left">Risk-free rates</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">1.60%-2.27</td>
<td style="font-size: 10pt; text-align: left">%</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">1.68</td>
<td style="font-size: 10pt; text-align: left">%</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>
Warrants.</i></b>In October 2017, the Company issued a warrant to
purchase 250,000 shares of common stock to a consultant for
servicesto be rendered. The warrant vests in six equal consecutive
monthly amounts at the end of each calendar month starting
October31, 2017, at an exercise price of $1.00 per share, for a
term of two years from the date of issuance.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 13.05pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Duringthe
six month period ended March 31, 2018, the Company recognized
$87,108 of expense related to warrants granted as stock
basedcompensation. There is no unamortized expense as of March 31,
2018 for outstanding warrants issued as stock based
compensation.Refer to the Common Stock Warrants table within this
note for information regarding all outstanding warrants.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>
Options.</i></b>In October 2017, the Company granted nonqualified
stock options to purchase an aggregate of 1,640,000 shares of
commonstock to certain directors, employees, executive officers and
key consultants. Other than the issuance of a stock option to
purchase80,000 shares of common stock issued to one key consultant,
one third of the shares of common stock subject to the stock
optionsbecame exercisable immediately, and one third of the shares
of common stock subject to the stock options will become
exercisableon each of October 16, 2018 and October 16, 2019. With
respect to the stock option to purchase 80,000 shares of common
stock issuedto one key consultant, one quarter of the shares of
common stock subject to the stock option vested immediately, and
the remainingthree quarters of the shares of common stock subject
to the stock option are exercisable upon the achievements of
certain milestonesin connection with the Company’s MAKO clinical
study. All but one milestone has been achieved. As such, the 20,000
sharesof common stock associated with this unmet performance
condition have been accounted for as a forfeiture and the remaining
60,000shares have vested as of March 31, 2018. The stock options
have an exercise price of $0.67 per share and expire on October
15,2022.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Duringthe
six month period ended March 31, 2018, the Company recognized
$643,889 of expense related to options granted. Unamortizedoption
expense as of March 31, 2018 for all options outstanding amounted
to $432,763. The Company expects to recognize this compensationcost
over a weighted-average period of 1.46 years.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Belowis
a table summarizing the Company’s activity for the six month period
ended March 31, 2018 (“Price” reflectsthe weighted average exercise
price per share):</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<table cellpadding="0" cellspacing="0" align="center" style=
"border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
Options</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; border-bottom: Black 1pt solid">
Price</td>
<td style=
"font-size: 10pt; font-weight: bold; text-align: center; vertical-align: bottom; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="width: 76%; font-size: 10pt">Outstanding at September
30, 2017</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
2,250,500</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 9%; font-size: 10pt; text-align: right">5.58</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt">Granted</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">1,640,000</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">0.67</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt">Exercised</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; text-align: left">Forfeited or
expired</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">(524,666</td>
<td style="font-size: 10pt; text-align: left">)</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">6.64</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt">Outstanding at March 31, 2018</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">3,365,834</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">3.02</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style="font-size: 10pt; padding-bottom: 2.5pt">Exercisable at
March 31, 2018</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
2,075,828</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2.5pt double">
$</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2.5pt double">
4.48</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2.5pt">
&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Asof
March 31, 2018, the outstanding options have a weighted average
remaining term of 4.22 years and no intrinsic
value.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>
RestrictedStock.</i></b> During the six month period ended March
31, 2018, the Company recognized $145,301 of expense related to
restrictedstock awards. As of March 31, 2018, there was no
remaining unamortized expense.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
</p>
<!-- Field: Page; Sequence: 9; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Belowis
a table summarizing the Company’s activity for the six month period
ended March 31, 2018:</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<table cellpadding="0" cellspacing="0" align="center" style=
"border-collapse: collapse; width: 80%">
<tr style="vertical-align: bottom">
<td style=
"font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; font-weight: bold; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Shares</td>
<td style=
"font-size: 10pt; font-weight: bold; padding-bottom: 1pt">
&nbsp;</td>
<td style=
"font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">
&nbsp;</td>
<td colspan="2" style=
"font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid">
Weighted<br />
Average Grant<br />
Date Fair<br />
Value</td>
<td style=
"font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 52%; font-size: 10pt; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
<font style="font-size: 10pt">Nonvested at September 30,
2017</font></td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 9%; font-size: 10pt; text-align: right">
270,179</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
<td style="width: 1%; font-size: 10pt">&nbsp;</td>
<td style="width: 1%; font-size: 10pt; text-align: left">$</td>
<td style="width: 12%; font-size: 10pt; text-align: right">
4.53</td>
<td style="width: 1%; font-size: 10pt; text-align: left">
&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
<font style="font-size: 10pt">Granted</font></td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">—</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
<font style="font-size: 10pt">Vested</font></td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt; text-align: right">270,179</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
<td style="font-size: 10pt">&nbsp;</td>
<td style="font-size: 10pt; text-align: left">$</td>
<td style="font-size: 10pt; text-align: right">4.53</td>
<td style="font-size: 10pt; text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"font-size: 10pt; text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 1pt">
<font style="font-size: 10pt">Forfeited</font></td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 1pt; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
—</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 1pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 1pt solid">
—</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">
&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2pt; padding-left: 8.65pt; text-indent: -8.65pt">
<font style="font-size: 10pt">Nonvested at March 31,
2018</font></td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 2pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; padding-bottom: 2pt; border-bottom: Black 2pt double">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2pt double">
—</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2pt">
&nbsp;</td>
<td style="font-size: 10pt; padding-bottom: 2pt">&nbsp;</td>
<td style=
"font-size: 10pt; text-align: left; border-bottom: Black 2pt double">
&nbsp;</td>
<td style=
"font-size: 10pt; text-align: right; border-bottom: Black 2pt double">
—</td>
<td style="font-size: 10pt; text-align: left; padding-bottom: 2pt">
&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE6
– COMMITMENTS AND CONTINGENCIES</b></font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>LegalProceedings</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany
has become involved in certain legal proceedings and claims which
arise in the normal course of business. Ifan unfavorable ruling
were to occur, there exists the possibility of a material adverse
impact on the Company’s resultsof operations, prospects, cash
flows, financial position and brand. On February 14, 2018,
plaintiff, Jeevesh Khanna,commenced an action in the Southern
District of New York, alleging that several current and former
officers violated federalsecurities laws between June 24, 2014 and
January 4, 2018. The plaintiffs did not quantify any alleged
damages in theircomplaint but, in addition to attorneys’ fees and
costs, they seek to recover damages on behalf of themselves and
otherpersons who purchased or otherwise acquired our stock during
the putative class period and purportedly suffered financialharm as
a result. We dispute these claims and intend to defend the matter
vigorously. This litigation could result insubstantial costs and a
diversion of management’s resources and attention, which could harm
the Company’s businessand the vlaue of the Company’s common stock.
&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OnMay
3, 2018, plaintiff Adele J. Barke, derivatively on behalf of Ohr
Pharmaceutical Inc. commenced an action againstMichael Ferguson,
Orin Hirschman, Thomas M. Riedhammer, June Almenoff and Jason
Slakter alleging that the action was broughtin the right and for
the benefit of Ohr seeking to remedy their “breach of fiduciary
duties, corporate waste and unjustenrichment that occurred between
June 24, 2014 and the present.” Thereafter the complaint largely
reiterated theallegations of the securities class action described
above. It does not quantify any alleged damages. The Company andthe
individuals dispute these claims and intend to defend the matter
vigorously. This litigation could result insubstantial costs and a
diversion of management’s resources and attention, which could harm
the Company’sbusiness and the value of the Company’s common
stock.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE7
– RELATED PARTY TRANSACTION</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheContract
Research Organization (“CRO”) that ran the Company’s clinical trial
contracted with JasonS. Slakter, M.D., P.C., d/b/a Digital
Angiography Reading Center (“DARC”), a well-known digital
readingcenter, which is owned by Dr. Jason Slakter, Ohr’s CEO,
pursuant to the Company’s related party transactionspolicy, with
the review and approval of the Audit Committee, to provide digital
reading and imaging services in connectionwith the clinical study.
During the six months ended March 31, 2018, and 2017, the Company’s
CRO was paid $899,001 and$55,398, respectively, for pass through
DARC expenses.<b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE8
– ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Duringthe
six month period ended March 31, 2018, the Company realized a gain
of $1,228,805 related to the settlement of accounts
payablebalances, long term liabilities, and a severance payable to
a former director.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE9
– SUBSEQUENT EVENTS&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
In April and May 2018, the Company sold or licensed certainassets
related to the squalamine program. We received upfront payments and
are eligible for additional payments upon the exerciseof an option
to purchase additional assets, and the achievement of development
and regulatory milestones, and future sales.</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0pt"></td>
<td style="width: 0.75in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
2.</b></font></td>
<td style="text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="ohrp10q033118a003"
id="ohrp10q033118a003"></a>Management’s Discussion and Analysis of
Financial Condition and Results of Operations.</b></font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ourdiscussion
and analysis of the business and subsequent discussion of financial
conditions may contain forward-looking statementswithin the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of1934, as amended.
Statements that are not historical in nature, including statements
about beliefs and expectations, are forward-lookingstatements.
Words such as “may,” “will,” “should,” “estimates,” “predicts,”
“believes,” “anticipates,” “plans,” “expects,” “intends” and
similarexpressions are intended to identify these forward-looking
statements, but are not the exclusive means of identifying such
statements.Such statements are based on currently available
operating, financial and competitive information and are subject to
various risksand uncertainties as described in greater detail in
Item IA, Part II, our “Risk Factors” beginning on page 14 of
thisReport. You are cautioned that these forward-looking statements
reflect management’s estimates only as of the date hereof,and we
assume no obligation to update these statements, even if new
information becomes available or other events occur in thefuture,
except as required by law. Actual future results, events and trends
may differ materially from those expressed in or impliedby such
statements depending on a variety of factors, including, but not
limited to those set forth in our filings with the Securitiesand
Exchange Commission (“SEC”). Specifically, and not in limitation of
these factors, we may alter our plans, strategies,objectives or
business.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 29.95pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 29.95pt; text-align: left; text-indent: 0in">
</p>
<!-- Field: Page; Sequence: 10; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 29.95pt; text-align: left; text-indent: 0in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CompanyOverview</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OhrPharmaceutical,
Inc. (“we,” “us,” “our,” “Ohr,” or the “Company”)is a
pharmaceutical company focused on the development of novel
therapeutics and delivery technologies for the treatment of
oculardisease.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 39.95pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RecentDevelopments</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OnJanuary
5, 2018, the Company reported topline data from the MAKO study
which did not meet its primary efficacy endpoint. The MAKOstudy
evaluated the efficacy and safety of topically administered
squalamine in combination with monthly Lucentis® injectionsfor the
treatment of wet-AMD. The primary efficacy endpoint was the mean
visual acuity gain at nine months, using a mixed effectsmodel for
repeated measures (MMRM) analysis. Subjects receiving squalamine
combination therapy (n=119) achieved a mean gain of8.33 letters
from baseline versus 10.58 letters from baseline with Lucentis®
monotherapy (n=118). There were no differencesin the safety profile
between the two treatment groups. Based on these results, we have
discontinued further development of squalamineand are evaluating
strategic alternatives to maximize shareholder value.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Aspart
of its review of strategic alternatives, the Company formed a
special committee of independent directors. The Boardof Directors
and the special committee have engaged Roth Capital Markets, LLC,
to advise it, the Board of Directors andmanagement, and to assist
in pursuing a range of strategic alternatives including some of the
following: license,divestiture, or other monetization of current
assets; license or acquisition of additional assets; merger, joint
venture,partnership, or other business combination with another
entity, public or private. Neither the Board nor the
specialcommittee has set a definitive timetable for completion of
this process. There can be no assurance that this process
willresult in a strategic alternative of any kind. The Company does
not intend to disclose developments or provide updates on
theprogress or status of this process unless it deems further
disclosure is appropriate or required.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Corporateand
Historical Information</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Weare
a Delaware corporation that was organized on August 4, 2009, as
successor to BBM Holdings, Inc. (formerly Prime Resource,Inc.,
which was organized March 29, 2002 as a Utah corporation) pursuant
to a reincorporation merger. On August 4, 2009, we reincorporatedin
Delaware as Ohr Pharmaceutical, Inc.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OnMay
30, 2014, we completed the ophthalmology assets acquisition (the 
“SKS Acquisition”) of the privately held SKSOcular LLC and its
affiliate, SKS Ocular 1 LLC (“SKS”). Under the terms of the
acquisition agreement, in exchangefor substantially all the assets
of SKS, Ohr made an upfront payment of $3.5 million in cash and
issued 1,194,862 shares of Ohrcommon stock to SKS. In addition, SKS
is eligible to receive up to an aggregate of 1,493,577 additional
shares of Ohr common stockin three contingent milestone payments,
each milestone resulting in the issuance of 497,859 shares of Ohr
common stock. Milestone1 required Ohr to demonstrate a consistent
long term release of a therapeutic agent above threshold
therapeutic levels in thetargeted ocular tissues of an animal
model. Ohr met this milestone in December 2015. Milestone 2
required the completion of apharmacodynamic study in an animal
model showing clinically relevant efficacy from a drug substance
released from SKS microparticleswithin 24 months of the date of the
closing of the SKS Acquisition. Ohr achieved the study results in
May 2016, and the Boardreviewed and approved Milestone 2 in July
2016. Milestone 3 requires, among other things, the approval of an
Investigational NewDrug Application (“IND”) within three years of
the date of the closing of the SKS Acquisition. We did not
achieveMilestone 3.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Simultaneouswith
the SKS Acquisition, Ohr completed a holding company reorganization
in which Ohr merged with a wholly owned subsidiary anda new parent
corporation succeeded Ohr as a public holding company under the
same name. The business operations of Ohr did notchange as a result
of the reorganization. The new holding company retained the name 
“Ohr Pharmaceutical, Inc.” Outstandingshares of the capital stock
of the former Ohr Pharmaceutical, Inc. were automatically
converted, on a share for share basis, intoidentical shares of
common stock of the new holding company.<b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>PRODUCTPIPELINE&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td>
<td style="width: 0.25in; text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</font></td>
<td style="text-align: justify"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">SQUALAMINELACTATE
OPHTHALMIC SOLUTION 0.2%</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>SqualamineLactate
Ophthalmic Solution 0.2% (“Squalamine”, also known as
OHR-102)</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Squalaminelactate
is a small molecule anti-angiogenic drug with a novel intracellular
mechanism of action. The drug acts against the developmentof
aberrant neovascularization by inhibiting multiple protein growth
factors of angiogenesis, including vascular endothelial
growthfactor (“VEGF”), platelet-derived growth factor (“PDGF”) and
basic fibroblast growth factor (“bFGF”).&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">InApril
2016, we commenced enrollment in the MAKO study. The study was a
multi-center, randomized, double-masked, placebo-controlledclinical
trial to evaluate the efficacy and safety of squalamine combination
therapy for the treatment of wet-AMD. Subjects wererandomized 1:1
to receive topical squalamine lactate ophthalmic solution, 0.2%, (
“squalamine”) twice daily (“BID”)and monthly Lucentis® injections (
“squalamine combination”) or topical placebo BID and monthly
Lucentis® injections(“Lucentis monotherapy”). Eligibility criteria
for the study eye included: newly diagnosed with wet-AMD and no
previoustreatment, occult neovascularization, if present, measured
less than 10mm<sup>2</sup> as assessed by fluorescein
angiography,and visual acuity between 20/40 and 20/320. A total of
237 subjects were randomized. Visual acuity was measured monthly
usingthe Early Treatment of Diabetic Retinopathy Study (ETDRS) eye
chart. The primary efficacy endpoint was the mean visual acuitygain
at nine months, using a mixed-effects model for repeated measures
(MMRM) analysis.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">
</p>
<!-- Field: Page; Sequence: 11; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OnJanuary
5, 2018, the Company reported topline data from the study which did
not meet its primary efficacy endpoint. The studyevaluated the
efficacy and safety of topically administered squalamine in
combination with monthly Lucentis® injections forthe treatment of
wet-AMD. The primary efficacy endpoint was the mean visual acuity
gain at nine months, using a mixed-effectsmodel for repeated
measures (MMRM) analysis. Subjects receiving squalamine combination
therapy (n=119) achieved a mean gain of8.33 letters from baseline
versus 10.58 letters from baseline with Lucentis® monotherapy
(n=118). There were no differencesin the safety profile between the
two treatment groups. Based on the results of the study, we are no
longer moving squalamineforward in clinical
development.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 32.25pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td>
<td style="width: 0.25in; text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</font></td>
<td style="text-align: justify"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">SKSSUSTAINED
RELEASE OCULAR DRUG DELIVERY PLATFORM TECHNOLOGY</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheSKS
sustained release technology was designed to develop best-in-class
drug formulations for ocular disease. The technology employsmicro
fabrication techniques to create nano, micro and macroparticle drug
formulations that can provide sustained and predictablerelease of a
therapeutic drug over a 3-6 month period. The versatility of this
delivery technology makes it well suited to potentiallydeliver
hydrophilic or hydrophobic small molecules, as well as proteins
with complex structures.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0.5in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">InFebruary
2017, the Company suspended activities at its lab facility in San
Diego, CA where research regarding the SKS sustainedrelease
technology had been conducted. However, the Company continues to
explore applications of its sustained release technologyand
potential avenues to monetize it.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td>
<td style="width: 0.25in; text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</font></td>
<td style="text-align: justify"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">CEPASSETS</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Aspart
of the SKS acquisition, we acquired the exclusive rights to an
animal model for dry-AMD whereby mice are immunized with
acarboxyethylpyrrole (“CEP”) which is bound to mouse serum albumin
(“MSA”) as well as the rights to produceand use CEP for research
and clinical applications. CEP is produced following the oxidation
of docosahexaenoic acid, which isabundant in the photoreceptor
outer segments that are phagocytosed by the retinal pigment
epithelium (“RPE”). A numberof CEP-adducted proteins have been
identified in proteomic studies examining the composition of drusen
and other subretinal depositsfound in the eyes of patients with
dry-AMD. Studies have shown that immunization of CEP-MSA can lead
to an ophthalmic phenotypevery similar to dry-AMD, including
deposition of complement in the RPE, thickening of the Bruch’s
membrane, upregulationof inflammatory cytokines, and immune cell
influx into the eye. Upon immunization with CEP, a marked decrease
in contrast sensitivitywhich precedes a loss of visual acuity, was
observed, similar to what occurs in many patients with dry AMD. A
collaborator ofthe Company is currently conducting research on the
CEP target to understand its role in undisclosed ocular diseases
and potentialfor use as a diagnostic agent. The Company has not yet
monetized this technology.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 29.95pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; width: 100%">
<tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td>
<td style="width: 0.25in; text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</font></td>
<td style="text-align: justify"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">NON-OPHTHALMOLOGYASSETS</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ohralso
owns various other compounds in earlier stages of development,
including the PTP1b inhibitor trodusquemine and related analogs.On
February 26, 2014, we entered into a Joint Venture Agreement and
related agreements with Cold Spring Harbor Laboratory (“CSHL”
)pursuant to which a joint venture, DepYmed Inc. (“DepYmed”), was
formed to further preclinical and clinical developmentof Ohr’s
trodusquemine and analogues as PTP1B inhibitors for oncology and
rare disease indications. DepYmed licensesresearch from CSHL and
intellectual property from us. Ohr is a passive joint venturer in
DepYmed.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidityand
Sources of Capital</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany
has limited working capital reserves with which to continue
development of its pharmaceutical products and
continuingoperations. The Company is reliant, at present, upon its
capital reserves for ongoing operations and has no
revenues.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Networking
capital reserves decreased from the end of the first quarter of the
Company’s 2018 fiscal year to the end of thesecond quarter by
$1,121,244 (to $4,105,064 from $5,226,308) primarily due to costs
related to the clinical trial. We expect ourcash burn to
significantly decrease in the remainder of fiscal 2018 as compared
to the same periods in 2017 as a result of thecompletion of the
MAKO study. Management has concluded that due to the conditions
described above, there is substantial doubtabout the Company’s
ability to continue as a going concern. The Company does not have a
bank line of credit or other fixedsource of capital reserves. When
it will need additional capital in the future, the Company will be
primarily reliant upon privateor public placement of its equity or
debt securities, or a transaction with a partner, but presently
there can be no assurancethat the Company will be successful in
such efforts. In April 2017, the Company closed a public offering
for net proceeds of approximately$12.7 million, and management
believes the Company has sufficient capital to meet its planned
operating needs through the endof calendar 2018.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Resultsof
Operations</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>ThreeMonths
Ended March 31, 2018 Compared to Three Months Ended March 31,
2017</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Resultsof
operations for the three months ended March 31, 2018 (“2018”)
reflect the following changes from the prior period(“2017”
).&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style=
"padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Change</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 64%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
General and administrative</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">591,184</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">1,404,061</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(812,877</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Research and development</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">1,801,946</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,993,928</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(4,191,982</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Depreciation and amortization</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">278,525</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">291,875</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(13,350</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Loss
on impairment of goodwill</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">740,912</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">740,912</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
Gain on settlement of liabilities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(1,228,805</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">—
</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(1,228,805</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Total Operating Expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">2,183,762</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">7,689,864</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(5,506,102</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Operating Loss</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(2,183,762</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(7,689,864</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">5,506,102</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
Other income (expense)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(1,005</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(208</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(797</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 2pt">
Net Loss</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
(2,184,767</td>
<td style="text-align: left; padding-bottom: 2pt">)</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
(7,690,072</td>
<td style="text-align: left; padding-bottom: 2pt">)</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
5,505,305</td>
<td style="text-align: left; padding-bottom: 2pt">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
</p>
<!-- Field: Page; Sequence: 12; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany
had no net revenues from operations in 2017 or 2018. Accordingly,
the Company had no cost of revenue from operations in2017 or
2018.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Generaland
administrative expenses from operations decreased $812,877 when
comparing 2018 to 2017. This decrease is a result of a reductionin
stock based compensation expense and employee headcount.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style="font: 10pt Times New Roman, Times, Serif">The Company
incurred $1,801,946 in research and development expensesin 2018
compared to $5,993,928 in 2017. The decrease is a result of
significant costs paid in 2017 related to the MAKO study inwet-AMD,
and settlement of accounts payable balances, long term liabilities,
and a severance payable to a former director.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciationand
amortization expense remained relatively stable with $291,875 in
2017 and $278,525 in 2018.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">In2018,
the Company had a gain on settlement of accounts payable balances,
long term liabilities, and a severance payable to aformer director.
totaling $1,228,805 compared to $0 in 2017.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">In2018,
the Company recorded an impairment on goodwill of $740,912 compared
to $0 in 2017. Due to the significant decrease instock value for
the three months ended March 31, 2018 the Company performed an
impairment test and concluded goodwill was impaired.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Forthe
three months ended March 31, 2018, the Company recognized a net
loss of $2,184,767 compared to a net loss of $7,690,072 forthe same
period in 2017. The decrease in net loss is primarily a result of
the completion of the MAKO study in wet-AMD. Untilthe Company is
able to generate revenues, management expects to continue to incur
net losses.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>SixMonths
Ended March 31, 2018 Compared to Six Months Ended March 31,
2017</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Resultsof
operations for the six months ended March 31, 2018 (“2018”) reflect
the following changes from the prior period(“2017”).</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
<td style=
"padding-bottom: 1pt; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2018</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
2017</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
<td colspan="2" style=
"font-weight: bold; text-align: center; border-bottom: Black 1pt solid">
Change</td>
<td style="font-weight: bold; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"width: 64%; text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
General and administrative</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">2,101,216</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">3,150,417</td>
<td style="width: 1%; text-align: left">&nbsp;</td>
<td style="width: 1%">&nbsp;</td>
<td style="width: 1%; text-align: left">$</td>
<td style="width: 9%; text-align: right">(1,049,201</td>
<td style="width: 1%; text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Research and development</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">4,189,677</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">10,925,072</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(6,735,395</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Depreciation and amortization</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">563,511</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">590,310</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(26,799</td>
<td style="text-align: left">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">Loss
on impairment of goodwill</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">740,912</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">—</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">740,912</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
Gain on settlement of liabilities</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(1,228,805</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">—
</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
(1,228,805</td>
<td style="text-align: left; padding-bottom: 1pt">)</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt">
Total Operating Expenses</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">6,366,511</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">14,665,799</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(8,299,288</td>
<td style="text-align: left">)</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
Operating Loss</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(6,366,511</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">(14,665,799</td>
<td style="text-align: left">)</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">8,299,288</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt">
&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td>&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
<td style="text-align: right">&nbsp;</td>
<td style="text-align: left">&nbsp;</td>
</tr>
<tr style="vertical-align: bottom; background-color: White">
<td style=
"text-align: left; padding-left: 8.65pt; text-indent: -8.65pt; padding-bottom: 1pt">
Other income (expense)</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
30,386</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
73</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
<td style="padding-bottom: 1pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 1pt solid">
&nbsp;</td>
<td style="text-align: right; border-bottom: Black 1pt solid">
30,313</td>
<td style="text-align: left; padding-bottom: 1pt">&nbsp;</td>
</tr>
<tr style=
"vertical-align: bottom; background-color: rgb(204,238,255)">
<td style=
"text-align: left; padding-left: 0.25in; text-indent: -8.65pt; padding-bottom: 2pt">
Net Loss</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
(6,336,125</td>
<td style="text-align: left; padding-bottom: 2pt">)</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
(14,665,726</td>
<td style="text-align: left; padding-bottom: 2pt">)</td>
<td style="padding-bottom: 2pt">&nbsp;</td>
<td style="text-align: left; border-bottom: Black 2pt double">
$</td>
<td style="text-align: right; border-bottom: Black 2pt double">
8,329,601</td>
<td style="text-align: left; padding-bottom: 2pt">&nbsp;</td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany
had no net revenues from operations in 2017 or 2018. Accordingly,
the Company had no cost of revenue from operations in2017 or
2018.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Generaland
administrative expenses from operations decreased $1,049,201 when
comparing 2018 to 2017. This decrease is a result of a reductionin
stock based compensation expense.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany
incurred $4,189,676,184 in research and development expenses in
2018 compared to $10,925,072 in 2017. The decrease isa result of
significant costs paid in 2017 related to the MAKO study in
wet-AMD, settlement of accounts payable balances, longterm
liabilities, and a severance payable to a former
director.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciationand
amortization expense remained relatively stable with $590,310 in
2017 and $563,511 in 2018.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
</p>
<!-- Field: Page; Sequence: 13; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">In2018,
the Company had a gain on settlement of accounts payable balances,
long term liabilities, and a severance payable to aformer director
totaling $1,228,805 compared to $0 in 2017.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">In2018,
the Company recorded an impairment on goodwill of $740,912 compared
to $0 in 2017. Due to the significant decrease instock value for
the three months ended March 31, 2018 the company performed an
impairment test and concluded goodwill was
impaired.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Forthe
six months ended March 31, 2018, the Company recognized a net loss
of $6,336,125 compared to a net loss of $14,665,726 forthe same
period in 2017. The decrease in net loss is primarily a result of
the completion of the MAKO study in wet-AMD. Untilthe Company is
able to generate revenues, management expects to continue to incur
net losses.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0pt"></td>
<td style="width: 0.75in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
3.</b></font></td>
<td style="text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="ohrp10q033118a004"
id="ohrp10q033118a004"></a>Quantitative and Qualitative
Risk.</b></font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Marketrisk
represents the risk of loss arising from adverse changes in
interest rates and foreign exchange rates. The Company doesnot have
any material exposure to interest rate or exchange rate
risk.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0pt"></td>
<td style="width: 0.75in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
4.</b></font></td>
<td style="text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="ohrp10q033118a005"
id="ohrp10q033118a005"></a>Controls and Procedures.</b></font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Evaluationof
Disclosure Controls and Procedures</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany,
under the supervision and with the participation of its management,
including the Chief Executive Officer and the ChiefFinancial
Officer, evaluated the effectiveness of the design and operation of
the Company’s “disclosure controls andprocedures” (as defined in
Rule 13a-15(e) under the Securities Exchange Act of 1934, as
amended) as of the end of the periodcovered by this Report. Based
on that evaluation, the Chief Executive Officer and the Chief
Financial Officer concluded the Company’sdisclosure controls were
effective. In designing and evaluating the disclosure controls and
procedures, our management, includingthe Chief Executive Officer
and the Chief Financial Officer, recognized that any controls and
procedures, no matter how well designedand operated, can only
provide reasonable assurance of achieving the desired control
objectives, and management was required toapply its judgment in
evaluating the cost-benefit relationship of possible controls and
procedures. Our disclosure controls andprocedures are designed to
provide a reasonable level of assurance of reaching our desired
disclosure controls objectives.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changesin
Internal Control Over Financial Reporting</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-indent: 0in; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Duringthe
period covered by this Report there has been no change in our
internal control over financial reporting that has
materiallyaffected, or is reasonably likely to materially affect,
our internal control over financial reporting.&nbsp;</font></p>
<p style=
"font: bold 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
</p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0pt"></td>
<td style="width: 0.75in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">PART
II</font></td>
<td style="text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><a name="ohrp10q033118a006"
id="ohrp10q033118a006"></a>OTHER INFORMATION</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
&nbsp;<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0pt"></td>
<td style="width: 0.75in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
1.</font></td>
<td style="text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><a name="ohrp10q033118a007"
id="ohrp10q033118a007"></a>Legal Proceedings.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OnFebruary
14, 2018, plaintiff, Jeevesh Khanna, commenced an action in the
Southern District of New York, alleging that severalcurrent and
former officers violated federal securities laws between June 24,
2014 and January 4, 2018. The plaintiffs didnot quantify any
alleged damages in their complaint but, in addition to attorneys’
fees and costs, they seek to recoverdamages on behalf of themselves
and other persons who purchased or otherwise acquired our stock
during the putative classperiod and purportedly suffered financial
harm as a result. We dispute these claims and intend to defend the
mattervigorously. This litigation could result in substantial costs
and a diversion of management’s resourcesand attention, which could
harm our business and the value of our common stock.
&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style="font: 10pt Times New Roman, Times, Serif">OnMay 3,
2018, plaintiff Adele J. Barke, derivatively on behalf of Ohr
Pharmaceutical Inc. commenced an action against MichaelFerguson,
Orin Hirschman, Thomas M. Riedhammer, June Almenoff and Jason
Slakter alleging that the action was brought in theright and for
the benefit of Ohr seeking to remedy their “breach of fiduciary
duties, corporate wasteand unjust enrichment that occurred between
June 24, 2014 and the present.” Thereafter the complaint largely
reiteratedthe allegations of the securities class action described
above. It does not quantify any alleged damages. The Company and
theindividuals dispute these claims and intend to defend the matter
vigorously. This litigation could result in substantialcosts and a
diversion of management’s resources and attention, which could harm
our business and the value of ourcommon stock.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0pt"></td>
<td style="width: 0.75in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Item
1A.</font></td>
<td style="text-align: left"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><a name="ohrp10q033118a008"
id="ohrp10q033118a008"></a>Risk Factors.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Youshould
carefully consider the following factors which may affect future
results of operations. If any of the adverse events describedbelow
actually occur, our business, financial condition and operating
results could be materially adversely affected and you maylose part
or all of the value of your investment. If you choose to invest in
our securities, you should be able to bear a completeloss of your
investment.</i></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>RisksRelating
to Our Financial Position and Need for Capital</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ourbusiness
was substantially dependent on the success of squalamine, which
recently failed to meet its primary efficacy endpointin the MAKO
Study. We are unable to identify a viable path forward for
continued development of this product
candidate.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Todate,
we have devoted a substantial portion of our research, development,
clinical efforts and financial resources toward thedevelopment of
squalamine for the treatment of wet-AMD. Squalamine was our lead
product candidate. On January 5, 2018, we announcedtopline results
from our MAKO Study which did not meet its primary efficacy
endpoint. We are unable to identify a viable planfor continued
clinical development of this product candidate. Because our
business was substantially dependent on the successof squalamine,
we have curtailed all of our activities on this program and may be
required to liquidate, dissolve or otherwisewind down our
operations if we are unable to execute on a strategic
alternative.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
</p>
<!-- Field: Page; Sequence: 14; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wemay
not be able to monetize the non squalamine assets, including the
SKS sustained release ocular drug delivery platform technologyor
the non-ophthalmology assets.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wemay
not be able to monetize any or some of the non-squalamine assets,
including the SKS sustained release ocular drug deliveryplatform
technology, the CEP assets or the non-ophthalmology assets,
including the PTP1b inhibitor trodusquemine and related analogs.In
that event, we may be constrained to write off those assets, in
whole or in part.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weare
subject to securities class action litigation and derivative
shareholder litigation.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Asa
result of our announcement of negative results from the MAKO Study,
our stock price declined substantially. On February 14,2018, a
securities class action litigation was brought against the Company,
Dr. Jason Slakter, Sam Backenroth, andIrach Tarapowela in federal
district court in the Southern District of New York. We dspute
these claims and intend to defendthe matter vigorously. This
litigation could result in substantial costs and a diversion of
management’s resources andattention, which could harm our business
and the value of our common stock.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin: 0 0.45pt 0 0; text-align: justify">
On May 3, 2018,plaintiff Adele J. Barke, derivatively on behalf of
the Company commenced an action against Michael Ferguson, Orin
Hirschman,Thomas M. Riedhammer, June Almenoff and Jason Slakter
alleging that the action was brought in the right and for the
benefitof Ohr seeking to remedy their “breach of fiduciary duties,
corporate waste and unjust enrichment that occurred betweenJune 24,
2014 and the present.” Thereafter, the complaint largely reiterated
the allegations of the securities classaction described above. It
too does not quantify any alleged damages. The Company and the
individuals dispute these claimsand intend to defend the matter
vigorously. However, this litigation could result in substantial
costs and a diversion ofmanagement’s resources and attention, which
could harm our business and the value of our common stock.</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ifwe
fail to continue to meet all applicable Nasdaq Capital Market
requirements and Nasdaq determines to delist our common stock,the
delisting could adversely affect the market liquidity of our common
stock and the market price of our common stock could
decrease.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ourcommon
stock is listed on the Nasdaq Capital Market. In order to maintain
our listing, we must meet minimum financial and otherrequirements,
including requirements for a minimum amount of capital, a minimum
price per share and continued business operationsso that we are not
characterized as a “public shell company.” If we are unable to
comply with Nasdaq’s listingstandards, Nasdaq may determine to
delist our common stock from the Nasdaq Capital Market. In the
event that our common stockis delisted from the Nasdaq Capital
Market and is not eligible for quotation or listing on another
market or exchange, tradingof our common stock could be conducted
only in the over-the-counter market on an electronic bulletin board
established forunlisted securities such as the Pink Sheets or the
OTC Markets. In such event, it could become more difficult to
dispose of, orobtain accurate price quotations for, our common
stock, and there would likely also be a reduction in our coverage
by securitiesanalysts and the news media, which could cause the
price of our common stock to decline further. Also, it may be
difficult forus to raise additional capital if we are not listed on
a major exchange.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OnFebruary
20, 2018, we received a notification letter from Nasdaq indicating
that the bid price of our common stock for the last30 consecutive
business days had closed below the minimum $1.00 per share required
for continued listing under Nasdaq ListingRule 5550(a). We were
provided a period of 180 calendar days, or until August 20, 2018,
to regain compliance. If the Company doesnot regain compliance
during the compliance period ending August 20, 2018, the Company
may be afforded a second 180 calendar dayperiod to regain
compliance. To qualify for the second compliance period, the
Company must (i) meet the continued listing requirementfor market
value of publicly-held shares and all other initial listing
standards for the Nasdaq Capital Market, with the exceptionof the
minimum closing bid price requirement and (ii) notify Nasdaq of its
intent to cure the deficiency. The Company can achievecompliance
with the minimum closing bid price requirement if, during either
compliance period, the minimum closing bid price pershare of the
Company’s common stock is at least $1.00 for a minimum of ten
consecutive business days.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheCompany
plans to carefully assess potential actions to regain compliance.
However, the Company may be unable to regain compliancewith the
minimum closing bid price requirement during the compliance
period(s), in which case the Company anticipates Nasdaq willprovide
a notice to the Company that its shares of common stock are subject
to delisting.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Thereis
no certainty that we will be able to execute on any strategic
alternatives to maximize shareholder value. If we are unableto
identify and execute such strategic alternatives, we may be forced
to cease operations.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Basedon
the results of the MAKO study, we began a comprehensive review of
strategic alternatives to maximize shareholder value. Aspart of its
review of strategic alternatives, the Company formed a special
committee of independent directors. The Boardof Directors and the
special committee have retained Roth Capital Markets, LLC, to
advise and assist us in this review.The strategic alternatives that
we are exploring, may include some or all of the following:
license, divestiture, ormonetization of current assets; license or
acquisition of additional assets; merger, joint venture,
partnership, or otherbusiness combination with another entity,
public or private. There can be no assurance that this review
process will resultin a transaction, or that if a transaction does
occur, that it will successfully enhance stockholder value. Our
expectedcash position, net of all liabilities, limits our
attractiveness to potential merger candidates and the value that we
mayreceive in such merger, joint venture, partnership, or other
business combination scenarios may be less than the currentmarket
value of the Company.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wehave
incurred significant losses and anticipate that we will incur
additional losses. We might never achieve or sustain
revenues.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wehave
experienced significant net losses since our inception. As of March
31, 2018, we had an accumulated deficit of approximately$114.4
million. We expect to continue to incur net losses. We do not
expect to receive, for at least the next several years, anyrevenues
from the commercialization of our product
candidates.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Thereport
of our independent registered public accounting firm expresses
substantial doubt about the Company’s ability to continueas a going
concern. Such “going concern” opinion could impair our ability to
obtain financing.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ourauditors,
MaloneBailey, LLP, have indicated in their report on the Company’s
financial statements for the fiscal yearended September 30, 2017
and for the subsequent quarterly periods to date, that conditions
exist that raise substantialdoubt about our ability to continue as
a going concern due to our recurring losses from operations. A 
“goingconcern” opinion could impair our ability to finance our
operations through the sale of equity, incurring debt, orother
financing alternatives. Our ability to continue as a going concern
will depend upon the availability and terms offuture funding. If we
are unable to achieve this goal, our business would be jeopardized
and the Company may not be ableto continue. If we ceased
operations, it is likely that all of our investors would lose their
investment.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
</p>
<!-- Field: Page; Sequence: 15; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style="font: 10pt Times New Roman, Times, Serif"><b>Wedepend
upon key officers and consultants in a competitive market for
skilled personnel. If we are unable to attractand retain key
personnel, it could adversely affect our ability to develop and
market our products. The negative result ofthe MAKO study and our
limited financial resources may make us less successful at
retaining employees.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style="font: 10pt Times New Roman, Times, Serif">Weare highly
dependent upon the principal members of our management team,
especially our Chief Executive Officer, Dr. Jason Slakter,and Vice
President of Business Development and Chief Financial Officer, Sam
Backenroth, as well as our directors and key consultants.A loss of
any of these personnel may have a material adverse effect on
aspects of our business.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style="font: 10pt Times New Roman, Times, Serif">Wealso
depend in part on obtaining the service of scientific personnel and
our ability to identify, hire and retain additional personnel.We
experience intense competition for qualified personnel, and the
existence of non-competition agreements between
prospectiveemployees and their former employers may prevent us from
hiring those individuals or subject us to suit from their former
employers.While we attempt to provide competitive compensation
packages to attract and retain key personnel, many of our
competitors arelikely to have greater resources and more experience
than we have, making it difficult for us to compete successfully
for keypersonnel.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style="font: 10pt Times New Roman, Times, Serif">Inaddition,
the announcement that we have commenced a review of strategic
alternatives may create uncertainty about our prospectsas an
independent business entity, and make it more difficult to attract
and retain qualified executive and other key personnel.The review
process may also be costly, time-consuming, divert the attention of
management and our employees or result in changesin our management
team or our board of directors, all of which could materially and
adversely affect our business. In addition,our stock price may
experience periods of increased volatility as a result of these
activities or related rumors and speculation.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font>&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
</p>
<p style=
"font: bold 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>RisksRelated
to Our Business and Industry</u></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wecurrently
do not have, and may never have, any products that generate
revenues.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Weare
a development stage pharmaceutical company and currently do not
have, and may never have, any products that generate
revenues.Investment in pharmaceutical product development is highly
speculative because it entails substantial upfront capital
expendituresand significant risk that any potential product
candidate will fail to demonstrate adequate effect or an acceptable
safety profile,gain regulatory approval and become commercially
viable. To date, we have not generated any product revenues from
our productcandidates. We cannot guarantee that any of our product
candidates will ever become marketable products.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weare
highly dependent upon our ability to raise additional capital.
Raising additional capital may cause dilution to our
stockholders,restrict our operations or require us to relinquish
rights to our technologies or product
candidates.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Untilsuch
time, if ever, as we can generate substantial product revenues, we
expect to finance our cash needs through a combinationof equity
offerings, debt financings, and partnerships. We do not have any
committed external source of funds. To the extent thatwe raise
additional capital through the sale of equity or convertible debt
securities, our stockholders’ ownership interestwill be diluted,
and the terms of these securities may include liquidation or other
preferences that adversely affect our stockholders’rights as
holders of our common stock. Debt financing and preferred equity
financing, if available, may involve agreements thatinclude
covenants limiting or restricting our ability to take specific
actions, such as incurring additional debt, making
capitalexpenditures or declaring dividends.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ifwe
raise capital through a partnership, we may have to relinquish
valuable rights to our technologies, future revenue
streams,research programs or product candidates or grant licenses
on terms that may not be favorable to us. If we are unable to
raiseadditional funds through equity or debt financings when
needed, we may be required to delay, limit, reduce or terminate our
productdevelopment or future commercialization efforts or grant
rights to develop and market products or product candidates that we
wouldotherwise prefer to develop and market ourselves, or cease
operations and liquidate.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weare
highly dependent upon our ability to enter into agreements with
collaborative partners to develop, commercialize, and marketour
products.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ourstrategy
is to seek a strategic commercial partner, or partners, such as
large pharmaceutical companies, with extensive experiencein the
development, commercialization, and marketing of ophthalmic and
non-ophthalmic products. To date, we have not entered intoany
strategic partnerships for any of our products. We face significant
competition in seeking appropriate strategic partners,and these
strategic partnerships can be intricate and time consuming to
negotiate and document. We may not be able to negotiatestrategic
partnerships on acceptable terms, or at all. We are unable to
predict when, if ever, we will enter into any strategicpartnerships
because of the numerous risks and uncertainties associated with
establishing strategic partnerships.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Whileour
strategy is to partner with an appropriate party, no assurance can
be given that any third party would be interested in partneringwith
us. We currently lack the resources to conduct clinical trials, to
manufacture any of our product candidates on a large scale,and we
have no sales, marketing or distribution capabilities. In the event
we are not able to enter into a collaborative agreementwith a
partner or partners, on commercially reasonable terms, or at all,
we may be unable to conduct clinical trials, or to commercializeour
products, which would have a material adverse effect upon our
business, prospects, financial condition, and results of
operations.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Evenif
we succeed in securing a partner, the partner collaborators may
fail to develop or effectively commercialize products usingour
product candidates or technologies. A partnership involving our
product candidates pose a number of risks, including the
following:&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
may not have sufficient resources or decide not to devote the
necessary resources due to internal constraints such as budget
limitations, lack of human resources, or a change in strategic
focus;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborators
may believe our intellectual property or the product candidate
infringes on the intellectual property rights of
others;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
may dispute their responsibility to conduct development and
commercialization activities pursuant to the applicable
collaboration, including the payment of related costs or the
division of any revenues;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
may decide to pursue a competitive product developed outside of the
partnership arrangement;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
may not be able to obtain, or believe they cannot obtain, the
necessary regulatory approvals;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
may delay the development or commercialization of our product
candidates in favor of developing or commercializing another party’
s product candidate; or</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">partners
may decide to terminate or not to renew the collaboration for these
or other reasons.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
</p>
<!-- Field: Page; Sequence: 16; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thus,should
the Company be successful in entering into a partnership agreement,
the agreements may not lead to development or commercializationof
product candidates in the most efficient manner or at all.
Partnership agreements are generally terminable without cause
onshort notice. We also face competition in seeking out
collaborators. If we are unable to secure new partners that achieve
thepartner’s objectives and meet our expectations, we may be unable
to advance our product candidates and may not generatemeaningful
revenues.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ifwe
are ever in a position to commercialize our product candidates, of
which there can be no assurance, we have no experience
selling,marketing or distributing products and no internal
capability to do so.&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wecurrently
have no sales, marketing or distribution capabilities and no
experience in building a sales force and distribution
capabilities.If we are ever in a position to commercialize our
product candidates, of which there can be no assurance, we must
develop internalsales, marketing and distribution capabilities,
which will be expensive and time consuming, or make arrangements
with third partiesto perform these services. If we decide to market
any of our products directly, we must commit significant financial
and managerialresources to develop a marketing and sales force with
technical expertise and with supporting distribution capabilities.
Buildingan in-house marketing and sales force with technical
expertise and distribution capabilities will require significant
expenditures,management resources and time. Factors that may
inhibit our efforts to commercialize our products directly and
without strategicpartners include:&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">our
inability to recruit and retain adequate numbers of effective sales
and marketing personnel;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
inability of sales personnel to obtain access to or persuade
adequate numbers of physicians to prescribe our
products;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
lack of complementary products to be offered by sales personnel,
which may put us at a competitive disadvantage relative to
companies with more extensive product lines; and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
costs and expenses associated with creating and sustaining an
independent sales and marketing organization.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wemay
not be successful in recruiting the sales and marketing personnel
necessary to sell our products and even if we do build asales
force, they may not be successful in marketing our products, which
would have a material adverse effect on our businessand results of
operations.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Werely,
and expect that we will continue to rely, on third parties to
conduct any future clinical trials for us. If such third partiesdo
not successfully carry out their duties or if we lose our
relationships with such third parties, our drug development
effortscould be delayed.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Weare
dependent on contract research organizations, third-party vendors
and independent investigators for preclinical testing, andclinical
trials related to our drug discovery and development efforts, and
we will likely continue to depend on them to assistin our future
discovery and development efforts. These parties are not our
employees, and we cannot control the amount or timingof resources
that they devote to our programs. If they fail to devote sufficient
time and resources to our drug development programsor if their
performance is substandard, it will delay the development and
commercialization of our product candidates. The partieswith which
we contract for execution of our clinical trials will play a
significant role in the conduct of the trials and thesubsequent
collection and analysis of data. Their failure to achieve their
research goals or otherwise meet their obligationson a timely basis
could adversely affect clinical development of our product
candidates.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Communicatingwith
outside parties can also be challenging, potentially leading to
mistakes as well as difficulties in coordinating activities.Outside
parties may:</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">have
staffing difficulties;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">fail
to comply with contractual obligations;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">experience
regulatory compliance issues;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">undergo
changes in priorities or become financially distressed;
or</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">form
relationships with other parties, some of which may be our
competitors.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thesefactors
may materially adversely affect the willingness or ability of third
parties to conduct our clinical trials and may subjectus to
unexpected cost increases that are beyond our control.
Nevertheless, we are responsible for ensuring that each of our
studiesis conducted in accordance with the applicable protocol,
legal, regulatory and scientific standards, and our reliance on
contractresearch organizations does not relieve us of our
regulatory responsibilities. We and our contract research
organizations arerequired to comply with applicable current Good
Laboratory Practice (“CGLP”), current Good Manufacturing Practice(
“CGMP”), and current Good Clinical Practice (“CGCP”) regulations
and guidelines enforced by the FDA andcomparable foreign regulatory
authorities for any products in clinical development. The FDA
enforces these CGCP regulations throughperiodic inspections of
clinical trial sponsors, principal investigators and trial sites.
If we or our contract research organizationsfail to comply with
applicable CGCP, the clinical data generated in our clinical trials
may be deemed unreliable and the FDA orcomparable foreign
regulatory authorities may require us to perform additional
clinical trials before approving our marketingapplications. We
cannot assure that, upon inspection, the FDA or any comparable
foreign regulatory authority will determine thatany of our clinical
trials comply with CGCP. In addition, our clinical trials must be
conducted with product produced under currentCGMP, regulations and
will require a large number of test subjects. Our failure or the
failure of our contract research organizationsto comply with these
regulations may require us to repeat clinical trials, which would
delay the regulatory approval process andcould also subject us to
enforcement action up to and including civil and criminal
penalties.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
</p>
<!-- Field: Page; Sequence: 17; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ifour
contract research organizations do not successfully carry out their
duties or if we were to lose relationships with contractresearch
organizations, our drug development efforts could be delayed or
terminated.&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ifwe
were to lose relationships with any one or more of these parties,
we could experience a significant delay in both identifyinganother
comparable provider and then contracting for its services. We may
be unable to retain an alternative provider on reasonableterms, if
at all. Even if we locate an alternative provider, it is likely
that this provider may need additional time to respondto our needs
and may not provide the same type or level of service as the
original provider. In addition, any provider that weretain will be
subject to current CGLP and CGCP, other regulatory standards, and
similar foreign standards, and we do not havecontrol over
compliance with these regulations by these providers. Consequently,
if these practices and standards are not adheredto by these
providers, the development and commercialization of our product
candidates could be delayed, and have a material adverseeffect on
our business.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ourproduct
candidates may not gain acceptance among physicians, patients, or
the medical community, thereby limiting our potentialto generate
revenues, which will undermine our future growth
prospects.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Evenif
our product candidates are approved for commercial sale by the FDA
or other regulatory authorities, including foreign
regulatoryauthorities, the degree of market acceptance of any
approved product candidate by physicians, healthcare professionals
and third-partypayors, and our profitability and growth will depend
on a number of factors, including:&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
ability to provide acceptable evidence of safety and
efficacy;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">pricing
and cost effectiveness, which may be subject to regulatory
control;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to obtain sufficient third-party insurance coverage or
reimbursement;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">effectiveness
of our or our collaborators’ sales and marketing
strategy;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">relative
convenience and ease of administration;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
prevalence and severity of any adverse side effects;
and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">availability
of alternative treatments.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ifany
product candidate that we develop does not provide a treatment
regimen that is at least as beneficial as the current standardof
care or otherwise does not provide some additional patient benefit
over the current standard of care, that product will notachieve
market acceptance and we will not generate sufficient revenues to
achieve profitability.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wemay
not be able to continue or fully exploit our partnerships with
outside scientific and clinical advisors, which could impairthe
progress of clinical trials and our research and development
efforts.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wework
with scientific and clinical advisors who are experts in the field
of ocular disorders. They advise us with respect to ourprograms.
These advisors are not our employees and may have other commitments
that would limit their future availability to us.If a conflict of
interest arises between their work for us and their work for
another entity, we may lose their services, whichmay impair our
reputation in the industry and delay the development or
commercialization of our product candidates.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Werely
completely on third-party manufacturers which may result in delays
in clinical trials, regulatory approvals and product
introductions.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wehave
no manufacturing facilities and do not have extensive experience in
the manufacturing of drugs or in designing drug
manufacturingprocesses. We will have to contract with third-party
manufacturers to produce, in collaboration with us, our product
candidatesfor clinical trials. If any of our product candidates are
approved by the FDA or other regulatory agencies, including
foreignregulatory agencies for commercial sale, we may need to
amend our contract with the manufacturer or contract with another
thirdparty to manufacture them in larger quantities. If we need to
enter into alternative arrangements, it could delay our
productdevelopment activities. Our reliance on these third parties
for development activities will reduce our control over these
activitiesbut will not relieve us of our responsibility to ensure
compliance with all required regulations and study and trial
protocols.If these third parties do not successfully carry out
their contractual duties, meet expected deadlines or conduct our
studiesin accordance with regulatory requirements or our stated
study and trial plans and protocols, or if there are disagreements
betweenus and these third parties, we will not be able to initiate,
or complete, or may be delayed in completing, the clinical
trialsrequired to support future approval of our product
candidates. In some such cases, we may need to locate an
appropriate replacementthird-party relationship, which may not be
readily available or with acceptable terms, which would cause
additional delay withrespect to the approval of our product
candidates and would thereby have a material adverse effect on our
business, financialcondition, results of operations and
prospects.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
</p>
<!-- Field: Page; Sequence: 18; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wehave
not entered into long-term agreements with third-party
manufacturers or with any alternate suppliers. Although we intendto
do so prior to any commercial launch of a product that is approved
by the FDA or any comparable foreign regulatory authoritiesin order
to ensure that we maintain adequate supplies of commercial drug
product, we may be unable to enter into such agreementsor do so on
commercially reasonable terms, which could delay a product launch
or subject our commercialization efforts to significantsupply risk.
In addition, reliance on third-party manufacturers entails risks to
which we would not be subject to if we manufacturedthe product
candidates ourselves, including:&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.5in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
inability to negotiate manufacturing agreements with third parties
under commercially reasonable terms;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.5in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced
control as a result of using third-party manufacturers for all
aspects of manufacturing activities;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.5in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">termination
or nonrenewal of manufacturing agreements with third parties in a
manner or at a time that is costly or damaging to us;
and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.5in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">disruptions
to the operations of manufacturers or suppliers of products and
services that are vital to our clinical program caused by
conditions unrelated to our business or operations, including
regulatory enforcement actions, and bankruptcy of the manufacturer
or supplier.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Anyof
these events could lead to clinical trial delays or failure to
obtain regulatory approval or impact our ability to
successfullycommercialize future product candidates. Some of these
events could be the basis for FDA or any comparable foreign
regulatoryauthority action, including injunction, recall, seizure
or total or partial suspension of product manufacture.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Contractmanufacturers
are subject to significant regulatory oversight with respect to
manufacturing products. The manufacturing facilitieson which we
rely may not continue to meet regulatory requirements and may have
limited capacity.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Anymanufacturers
of our product candidates are obliged to operate in accordance with
FDA-mandated CGMPs. In addition,the facilities that would be used
by contract manufacturers or other third party manufacturers to
manufacture ourproduct candidates must be approved by the FDA or
other foreign regulatory authority pursuant to inspections that
will beconducted after we request regulatory approval from the FDA
or other foreign regulatory authority. A failure of anycontract
manufacturers to establish and follow CGMPs and to document their
adherence to such practices may lead tosignificant delays in
development, or in clinical trials or in obtaining regulatory
approval of product candidates or theultimate launch of products
based on our product candidates into the market. Furthermore, all
of our future contractmanufacturers are likely to be engaged with
other companies to supply and/or manufacture materials or products
for suchcompanies, which exposes them to regulatory risks for the
production of such materials and products. As a result, failure
tosatisfy the regulatory requirements for the production of those
materials and products may affect the regulatory clearance ofthe
contract manufacturers’ facilities generally. Failure by
third-party manufacturers or us to comply with
applicableregulations could result in sanctions being imposed on
us, including fines, injunctions, civil penalties, failure of
thegovernment to grant pre-market approval of drugs, delays,
suspension or withdrawal of approvals, seizures or recalls
ofproducts, operating restrictions, and criminal prosecutions. Many
aspects of the clinical trial and manufacturing process areoutside
of our control. The facilities and quality systems of third-party
contractors must pass a pre-approval inspection forcompliance with
the applicable regulations as a condition of regulatory approval of
product candidates. In addition, theregulatory authorities may, at
any time, audit or inspect a manufacturing facility involved with
the preparation of ourproduct candidates or the associated quality
systems for compliance with the regulations applicable to the
activities beingconducted. If these facilities do not pass a
pre-approval plant inspection, FDA approval of the products will
not begranted.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Theregulatory
authorities also may, at any time following approval of a product
for sale, audit our manufacturing facilities or thoseof our
third-party manufacturers. If any such inspection or audit
identifies a failure to comply with applicable regulations orif a
violation of our product specifications or applicable regulations
occurs independent of such an inspection or audit, we orthe
relevant regulatory authority may require remedial measures that
may be costly and/or time-consuming for us or our
third-partymanufacturers to implement and that may include the
temporary or permanent suspension of a clinical trial or commercial
salesor the temporary or permanent closure of a manufacturing
facility. Any such remedial measures imposed upon us or third
partieswith whom we contract could materially harm our
business.</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Developmentsby
competitors may render our products or technologies obsolete or
non-competitive which would have a material adverse effecton our
business and results of operations.</b></font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -0.5pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wecompete
against fully integrated pharmaceutical companies and smaller
companies that are collaborating with larger
pharmaceuticalcompanies, academic institutions, government agencies
and other public and private research organizations. Our drug
candidateswill have to compete with existing therapies and
therapies under development by our competitors. In addition, our
commercial opportunitiesmay be reduced or eliminated if our
competitors develop and market products that are less expensive,
more effective or safer thanour drug products. Other companies have
drug candidates in various stages of preclinical or clinical
development to treat diseasesfor which we are also seeking to
develop drug products. Some of these potential competing drugs are
further advanced in developmentthan our drug candidates and may be
commercialized earlier. Even if we are successful in developing
effective drugs, our productsmay not compete successfully with
products produced by our competitors. Most of our competitors,
either alone or together withtheir collaborative partners, operate
larger research and development programs, have larger staffing and
facilities, and havesubstantially greater financial resources than
we do, as well as significantly greater experience
in:&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0in">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">developing
drugs;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">undertaking
preclinical testing and human clinical trials;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
FDA and other regulatory approvals, including foreign regulatory
approvals, of drugs;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">formulating
and manufacturing drugs; and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman,serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
<td style="width: 0in"></td>
<td style="width: 0.25in"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style="text-align: justify; padding-right: 0.65pt"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">launching,
marketing and selling drugs.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
</p>
<!-- Field: Page; Sequence: 19; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman,serif">
&nbsp;</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Theseorganizations
also compete with us to attract qualified personnel, acquisitions
and joint venture candidates and for other
collaborations.Activities of our competitors may impose
unanticipated costs on our business which would have a material
adverse effect on ourbusiness and results of operations.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font: 10pt Times New Roman, Times, Serif">Ouremployees, partners,
independent contractors, principal investigators, consultants,
vendors and contract research organizationsmay engage in misconduct
or other improper activities, including noncompliance with
regulatory standards and requirements.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Weare
exposed to the risk that our employees, partners, independent
contractors, principal investigators, consultants, vendors
andcontract research organizations may engage in fraudulent or
other illegal activity with respect to our business. Misconduct
bythese employees could include intentional, reckless and/or
negligent conduct or unauthorized activity that violates: (1) FDA
orany comparable foreign regulatory authority regulations,
including those laws requiring the reporting of true, complete and
accurateinformation to the FDA or any comparable foreign regulatory
authority; (2) manufacturing standards; (3) federal, state and
foreignhealthcare fraud and abuse laws and regulations; or (4) laws
that require the true, complete and accurate reporting of
financialinformation or data. Activities subject to these laws also
involve the improper use of information obtained in the course of
clinicaltrials, or illegal misappropriation of drug product, which
could result in regulatory sanctions and serious harm to our
reputation.Any incidents or any other conduct that leads to an
employee receiving an FDA or other regulatory authority debarment
could resultin a loss of business from our partners and severe
reputational harm. We have adopted a Code of Business Conduct and
Ethics, butit is not always possible to identify and deter employee
misconduct, and the precautions we take to detect and prevent this
activitymay not be effective in controlling unknown or unmanaged
risks or losses or in protecting us from governmental
investigationsor other actions or lawsuits stemming from a failure
to be in compliance with such laws or regulations. If any such
actions areinstituted against us, and we are not successful in
defending ourselves or asserting our rights, those actions could
have a significantimpact on our business, including the imposition
of civil, criminal and administrative penalties, damages, monetary
fines, contractualdamages, reputational harm, diminished profits
and future earnings, and curtailment of our operations, any of
which could adverselyaffect our ability to operate our business,
operating results and financial condition.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anyfuture
acquisitions we make of companies or technologies may result in
disruption to our business or distraction of our management,due to
difficulties in assimilating acquired personnel and
operations.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wemay
acquire or make investments in complementary businesses,
technologies, services or products which complement our
pharmaceuticaloperations if appropriate opportunities arise. From
time to time we engage in discussions and negotiations with
companies regardingour acquiring or investing in such companies’
businesses, products, services or technologies, in the ordinary
course ofour business. We cannot be assured that we will be able to
identify future suitable acquisition or investment candidates, or
ifwe do identify suitable candidates, that we will be able to make
such acquisitions or investments on commercially acceptable termsor
at all. If we acquire or invest in another company, we could have
difficulty in assimilating that company’s personnel,operations,
technology and software. In addition, the key personnel of the
acquired company may decide not to work for us. Ifwe make other
types of acquisitions, we could have difficulty in integrating the
acquired products, services or technologies intoour operations.
These difficulties could disrupt our ongoing business, distract our
management and employees, increase our expensesand adversely affect
our results of operations. Furthermore, we may incur indebtedness
or issue equity securities to pay for anyfuture acquisitions. The
issuance of equity securities would be dilutive to our existing
stockholders. However, we currently donot have any agreement to
enter into any material investment or acquisition
transaction.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Securitybreaches
and other disruptions could compromise our information and expose
us to liability, which would cause our business andreputation to
suffer.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Westore
sensitive data, including intellectual property, our proprietary
business information and personally identifiable informationof our
employees, in our data centers and on our networks. The secure
maintenance of this information is critical to our
operations.Despite our security measures, our information
technology and infrastructure may be vulnerable to attacks by
hackers or breacheddue to employee error, malfeasance or other
disruptions. Any such breach could compromise our networks and the
information storedthere could be accessed, publicly disclosed, lost
or stolen. Any such access, disclosure or other loss of information
could resultin legal claims or proceedings, liability under laws
that protect the privacy of personal information, regulatory
penalties, anddamage our reputation.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
</p>
<!-- Field: Page; Sequence: 20; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ourbusiness
and operations would suffer in the event of system
failures.&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Despitethe
implementation of security measures, our internal computer systems
and those of our contractors and consultants are vulnerableto
damage from computer viruses, unauthorized access, natural
disasters, terrorism, war and telecommunication and electrical
failures.Such an event could cause interruption of our operations.
For example, the loss of data from clinical trials for our product
candidatescould result in delays in our regulatory approval efforts
and significantly increase our costs. To the extent that any
disruptionor security breach were to result in a loss of or damage
to our data, or inappropriate disclosure of confidential or
proprietaryinformation, we could incur liability and the
development of our product candidates could be delayed.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>RisksRelated
to FDA, Comparable Foreign Regulatory Authority and Healthcare
Regulations</u></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weface
heavy government regulation. FDA regulatory approval and/or
comparable foreign regulatory authority’s approval of ourproducts
is uncertain.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Theresearch,
testing, manufacturing and marketing of drug products are subject
to extensiveregulation by federal, state and local government
authorities, including the FDA or any comparable foreign regulatory
authority.To obtain regulatory approval of a product, we must
demonstrate to the satisfaction of the applicable regulatory agency
that,among other things, the product is safe and effective for its
intended use. In addition, we must show that the manufacturing
facilitiesused to produce the products are in compliance with
current Good Manufacturing Practices regulations.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Theprocess
of obtaining FDA and other required regulatory approvals, including
foreign regulatory approvals and clearances, willrequire us to
expend substantial time and capital. Despite the time and expense
expended, regulatory approval is never guaranteed.The number of
preclinical and clinical trials that will be required for FDA
approval, or any comparable foreign regulatory authority’sapproval,
varies depending on the drug candidate, the disease or condition
for which the drug candidate is in development, andthe requirements
applicable to that particular drug candidate. The FDA or other
foreign health authority can delay, limit or denyapproval of a drug
candidate for many reasons, including that:&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">a
drug candidate may not be shown to be safe or
effective;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA or any comparable foreign regulatory authority may not approve
our manufacturing process;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA or any comparable foreign regulatory authority may interpret
data from preclinical and clinical trials in different ways than we
do; and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA may not meet, or may extend, the Prescription Drug User Fee Act
date with respect to a particular NDA.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Forexample,
if certain of our methods for analyzing our trial data are not
accepted by the FDA or foreign regulatory authority, wemay fail to
obtain regulatory approval for our product candidates. Moreover, if
and when our products do obtain marketing approval,the marketing,
distribution and manufacture of such products would remain subject
to extensive ongoing regulatory requirements.Failure to comply with
applicable regulatory requirements could result in:</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">warning
letters;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">fines;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">civil
penalties;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">recall
or seizure of products;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">total
or partial suspension of production;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
of the government to grant future approvals;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal
of approvals; and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal
prosecution.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Anydelay
or failure by us to obtain regulatory approvals for our product
candidates could diminish competitive advantages that wemay attain
and would adversely affect the marketing of our products. We have
not received regulatory approval to market any ofour product
candidates in any jurisdiction.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
</p>
<!-- Field: Page; Sequence: 21; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Followingregulatory
approval of any of our drug candidates, we will be subject to
ongoing regulatory obligations and restrictions, whichmay result in
significant expense and limit our ability to commercialize our
potential products.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Withregard
to our drug candidates, if any, approved by the FDA or by another
regulatory authority, including a foreign regulatoryauthority, we
are held to extensive regulatory requirements over product
manufacturing, labeling, packaging, adverse event
reporting,storage, advertising, promotion and record keeping.
Regulatory approvals may also be subject to significant limitations
on theindicated uses or marketing of the drug candidates.
Potentially costly follow-up or post-marketing clinical studies may
be requiredas a condition of approval to further substantiate
safety or efficacy, or to investigate specific issues of interest
to the regulatoryauthority. Previously unknown problems with the
drug candidate, including adverse events of unanticipated severity
or frequency,may result in restrictions on the marketing of the
drug, and could include withdrawal of the drug from the
market.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Inaddition,
the law or regulatory policies governing pharmaceuticals may
change. New statutory requirements may be enacted or
additionalregulations may be enacted that could prevent or delay
regulatory approval of our drug candidates. We cannot predict the
likelihood,nature or extent of adverse government regulation that
may arise from future legislation or administrative action, either
in theUnited States or elsewhere. If we are not able to maintain
regulatory compliance, we might not be permitted to market our
drugsand which could have a material adverse effect on our business
and competitive position.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Healthcarepolicy
changes, including proposals to reform the U.S. healthcare system,
may harm our future business.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcarecosts
have risen significantly over the past decade. There have been and
continue to be proposals by legislators, regulators andthird-party
payors to keep these costs down. Certain proposals, if passed,
would impose limitations on the prices we will be ableto charge for
the products that we are developing, or the amounts of
reimbursement available for these products from
governmentalagencies thirdparty payors. These limitations could in
turn reduce the amount of investment into development, and the
amount ofrevenues that we will be able to generate in the future
from sales of our products and licenses of our
technology.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">InMarch
2010, the U.S. Congress enacted healthcare reform legislation that
may significantly impact the pharmaceutical industry.In addition to
requiring most individuals to have health insurance and
establishing new regulations on health plans, this
legislationrequires discounts under the Medicare drug benefit
program and increased rebates on drugs covered by Medicaid. In
addition, thelegislation imposes an annual fee, which will increase
annually, on sales by branded pharmaceutical manufacturers starting
in2011. The financial impact of these discounts, increased rebates
and fees and the other provisions of the legislation on our
businessis unclear and there can be no assurance that our business
will not be materially adversely affected. In addition, these and
otherongoing initiatives in the United States have increased and
will continue to increase pressure on drug pricing. The
announcementor adoption of any government initiatives could have an
adverse effect on potential revenues from any product that we may
successfullydevelop.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Varioushealthcare
reform proposals have also emerged at the state level. We cannot
predict what healthcare initiatives, if any, willbe implemented at
the federal or state level, or the effect any future legislation or
regulation will have on us. However, anexpansion in government’s
role in the U.S. healthcare industry may lower the future revenues
for the products we are developingand adversely affect our future
business, possibly materially.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>RisksRelated
to Our Intellectual Property</u></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ourability
to compete may be undermined if we do not adequately protect our
proprietary rights.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ourcommercial
success depends on obtaining and maintaining proprietary rights to
our product candidates and technologies andtheir uses, as well as
successfully defending these rights against third-party challenges.
We will be able to mosteffectively protect our product candidates,
technologies, and their uses from unauthorized use by third parties
to the extentthat valid and enforceable patents, or effectively
protected trade secrets, cover them. Nonetheless, the issued
patents andpatent applications covering our programs remain subject
to uncertainty due to a number of factors, including:</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may not have been the first to make one or more of the inventions
covered by our pending patent applications or issued
patents;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may not have been the first to file patent applications for one or
more of our product candidates or the technologies we rely
upon;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may independently develop similar or alternative technologies or
duplicate any of our technologies;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 16.15pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">our
disclosures in a particular patent application may be determined to
be insufficient to meet the statutory requirements for
patentability;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">one
or more of our pending patent applications may not result in issued
patents;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may not seek or obtain patent protection in all countries that will
eventually provide a significant business opportunity;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">one
or more patents issued to us or to our collaborators may not
provide a basis for commercially viable products, may not provide
us with any competitive advantages or may be challenged by third
parties;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may fail to file for patent protection in all of the countries
where patent protection will ultimately be necessary or fail to
comply with other procedural, documentary, fee payment or other
provisions during the patent process in any such country, and we
may be precluded from filing at a later date or may lose some or
all patent rights in the relevant jurisdiction;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">one
or more of our technologies may not be patentable;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<!-- Field: Page; Sequence: 22; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may design around one or more of our patent claims to produce
competitive products which fall outside of the scope of our
patents;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may identify prior art which could invalidate our patents;
or</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
to patent laws may limit the exclusivity rights of patent
holders.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Evenif
we have or obtain patents covering our product candidates or
technologies, we may still be barred from making, using and
sellingone or more of our product candidates or technologies
because of the patent rights of others. Others have or may have
filed, andin the future are likely to file, patent applications
covering compounds, assays, therapeutic products and delivery
systems, includingsustained release delivery, that are similar or
identical to ours. Numerous U.S. and foreign issued patents and
pending patentapplications owned by others exist in the area of
ocular disorders. These could materially affect our ability to
develop our productcandidates or sell our products. Because patent
applications can take years to issue, there may be currently
pending applications,unknown to us, that may later result in issued
patents that our product candidates or technologies may infringe.
These patentapplications may have priority over one or more patent
applications filed by us.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ifour
competitors have prepared and filed patent applications in the
United States that claim technology we also claim, we may haveto
participate in interference proceedings required by the United
States Patent and Trademark Office to determine priority
ofinvention, which could result in substantial costs, even if we
ultimately prevail. Results of interference proceedings are
highlyunpredictable and may result in us having to try to obtain
licenses in order to continue to develop or market certain of our
drugproducts.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disputesmay
arise regarding the ownership or inventorship of our inventions. It
is difficult to determine how such disputes would be
resolved.Others may challenge the validity of our patents. If one
or more of our patents are found to be invalid, we will lose the
abilityto exclude others from making, using or selling the
inventions claimed therein.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Someof
our research collaborators and scientific advisors have rights to
publish data and information to which we have rights.
Additionally,employees whose positions may be eliminated may seek
future employment with our competitors. Each of our employees is
requiredto sign a confidentiality agreement and invention
assignment agreement with us at the time of hire. While such
arrangements areintended to enable us to better control the use and
disclosure of our proprietary property and provide for our
ownership of proprietarytechnology developed on our behalf, they
may not provide us with meaningful protection for such property and
technology in theevent of unauthorized use or disclosure. In
addition, technology that we may in-license may become important to
some aspects ofour business. We generally will not control all of
the patent prosecution, maintenance or enforcement of in-licensed
technology.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Werely
on confidentiality agreements that could be breached and may be
difficult to enforce which could have a material adverseeffect on
our business and competitive position.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ourpolicy
is to enter agreements relating to the non-disclosure of
confidential information with third parties, including our
contractors,consultants, advisors and research collaborators, as
well as agreements that purport to require the disclosure and
assignmentto us of the rights to the ideas, developments,
discoveries and inventions of our employees and consultants while
we employ them.However, these agreements can be difficult and
costly to enforce. Moreover, to the extent that our contractors,
consultants, advisorsand research collaborators apply or
independently develop intellectual property in connection with any
of our projects, disputesmay arise as to the proprietary rights to
this type of information. If a dispute arises, a court may
determine that the rightbelongs to a third party, and enforcement
of our rights can be costly and unpredictable. In addition, we rely
on trade secretsand proprietary know-how that we will seek to
protect in part by confidentiality agreements with our employees,
contractors, consultants,advisors or others. In addition, courts
outside the United States may be less willing to protect trade
secrets. Despite the protectivemeasures we employ, we still face
the risk that:&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">these
agreements may be breached;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">these
agreements may not provide adequate remedies for the applicable
type of breach; or</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">our
trade secrets or proprietary know-how will otherwise become
known.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Anybreach
of our confidentiality agreements or our failure to effectively
enforce such agreements would have a material adverse effecton our
business and competitive position.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ifwe
infringe the rights of third parties, we could be prevented from
selling products, forced to pay damages and required to
defendagainst litigation which could result in substantial costs
and may have a material adverse effect on our business and
resultsof operations.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wehave
not received to date any claims of infringement by any third
parties. However, as our product candidates progress into
clinicaltrials and commercialization, if at all, our public profile
and that of our product candidates may be raised and generate
suchclaims. Defending against such claims, and occurrence of a
judgment adverse to us, could result in unanticipated costs and
mayhave a material adverse effect on our business and competitive
position. If our products, methods, processes and other
technologiesinfringe the proprietary rights of other parties, we
could incur substantial costs and we may have to:</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">obtain
licenses, which may not be available on commercially reasonable
terms, if at all;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">redesign
our products or processes to avoid infringement;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">stop
using the subject matter claimed in the patents held by others,
which could cause us to lose the use of one or more of our drug
candidates;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<!-- Field: Page; Sequence: 23; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">defend
litigation or administrative proceedings that may be costly whether
we win or lose, and which could result in a substantial diversion
of management resources; or</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">pay
damages.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Anycosts
incurred in connection with such events or the inability to sell
our products may have a material adverse effect on ourbusiness and
results of operations.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectualproperty
litigation is increasingly common and increasingly expensive and
may result in restrictions on our business and substantialcosts,
even if we prevail.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Patentand
other intellectual property litigation is becoming more common in
the pharmaceutical industry. Litigation is sometimes necessaryto
defend against or assert claims of infringement, to enforce our
patent rights, including those we have licensed from others,to
protect trade secrets or to determine the scope and validity of
proprietary rights of third parties. Currently, no third partyis
asserting that we are infringing upon their patent rights or other
intellectual property, nor are we aware or believe thatwe are
infringing upon any third party’s patent rights or other
intellectual property. We may, however, be infringing upona third
party’s patent rights or other intellectual property, and
litigation asserting such claims might be initiated inwhich we
would not prevail, or we would not be able to obtain the necessary
licenses on reasonable terms, if at all. All suchlitigation,
whether meritorious or not, as well as litigation initiated by us
against third parties, is time-consuming and veryexpensive to
defend or prosecute and to resolve. In addition, if we infringe the
intellectual property rights of others, we couldlose our right to
develop, manufacture or sell our products or could be required to
pay monetary damages or royalties to licenseproprietary rights from
third parties. An adverse determination in a judicial or
administrative proceeding or a failure to obtainnecessary licenses
could prevent us from manufacturing or selling our products, which
could harm our business, financial conditionand
prospects.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Adispute
concerning the infringement or misappropriation of our proprietary
rights or the proprietary rights of others could betime consuming
and costly, and an unfavorable outcome could harm our
business.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereis
significant litigation in our industry regarding patent and other
intellectual property rights. While we are not currentlysubject to
any pending intellectual property litigation, and are not aware of
any such threatened litigation, we may be exposedto future
litigation by third parties based on claims that our product
candidates, technologies or activities infringe the
intellectualproperty rights of others. If our drug development
activities are found to infringe any such patents, we may have to
pay significantdamages or seek licenses to such patents. If our
products are found to infringe any such patents, we may have to pay
significantdamages or seek licenses to such patents. A patentee
could prevent us from making, using or selling the patented
compounds. Wemay need to resort to litigation to enforce a patent
issued to us, protect our trade secrets or determine the scope and
validityof third-party proprietary rights. From time to time, we
may hire scientific personnel formerly employed by other companies
involvedin one or more areas similar to the activities conducted by
us. Either we or these individuals may be subject to allegations
oftrade secret misappropriation or other similar claims as a result
of their prior affiliations. If we become involved in litigation,it
could consume a substantial portion of our managerial and financial
resources, regardless of whether we win or lose. We alsomay not be
able to afford the costs of litigation.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Thepatent
applications of pharmaceutical and biotechnology companies involve
highly complex legal and factual questions, which, ifdetermined
adversely to us, could negatively impact our patent
position.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thepatent
positions of pharmaceutical and biotechnology companies can be
highly uncertain and involve complex legal and factual questions.No
consistent policy regarding the breadth of claims allowed in
biotechnology patents has emerged to date. The U.S. Patent
andTrademark Office’s standards are uncertain and could change in
the future. Consequently, the issuance and scope of patentscannot
be predicted with certainty. Patents, if issued, may be challenged,
invalidated or circumvented. U.S. patents and patentapplications
may also be subject to interference or derivation proceedings, and
U.S. patents may be subject to inter partes review,post grant
review and ex parte reexamination proceedings in the U.S. Patent
and Trademark Office (and foreign patents may be subjectto
opposition or comparable proceedings in the corresponding foreign
patent office), which proceedings could result in eitherloss of the
patent or denial of the patent application or loss or reduction in
the scope of one or more of the claims of the patentor patent
application. Similarly, opposition or invalidity proceedings could
result in loss of rights or reduction in the scopeof one or more
claims of a patent in foreign jurisdictions. Such interference,
inter partes review, post grant review and ex partereexamination
and opposition proceedings may be costly. Accordingly, rights under
any issued patents may not provide us with sufficientprotection
against competitive products or processes.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Changesin
or different interpretations of patent laws in the United States
and foreign countries may permit others to use our discoveriesor to
develop and commercialize our technology and products without
providing any compensation to us or may limit the number ofpatents
or claims we can obtain. In particular, there have been proposals
to shorten the exclusivity periods available under U.S.patent law
that, if adopted, could substantially harm our business. The
product candidates that we are developing are protectedby
intellectual property rights, including patents and patent
applications. If any of our product candidates becomes a
marketableproduct, we will rely on our exclusivity under patents to
sell the compound and recoup our investments in the research and
developmentof the compound. If the exclusivity period for patents
is shortened, then our ability to generate revenues without
competitionwill be reduced and our business could be materially
adversely impacted. The laws of some countries do not protect
intellectualproperty rights to the same extent as U.S. laws, and
those countries may lack adequate rules and procedures for
defending ourintellectual property rights. For example, some
countries, including many in Europe, do not grant patent claims
directed to methodsof treating humans and, in these countries,
patent protection may not be available at all to protect our
product candidates. Inaddition, U.S. patent laws may change, which
could prevent or limit us from filing patent applications or patent
claims to protectour products or technologies or limit the
exclusivity periods that are available to patent holders. For
example, the Leahy-SmithAmerica Invents Act, or the Leahy-Smith
Act, was recently signed into law and includes a number of
significant changes to U.S.patent law. These include changes to
transition from a “first-to-invent” system to a “first-to-file”
systemand to the way issued patents are challenged. These changes
may favor larger and more established companies that have more
resourcesto devote to patent application filing and prosecution.
The U.S. Patent and Trademark Office has been in the process of
implementingregulations and procedures to administer the
Leahy-Smith Act, and many of the substantive changes to patent law
associated withthe Leahy-Smith Act may affect our ability to
obtain, enforce or defend our patents. Accordingly, it is not clear
what, if any,impact the LeahySmith Act will ultimately have on the
cost of prosecuting our patent applications, our ability to obtain
patentsbased on our discoveries and our ability to enforce or
defend our issued patents.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
</p>
<!-- Field: Page; Sequence: 24; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ifwe
fail to obtain and maintain patent protection and trade secret
protection of our product candidates, proprietary technologiesand
their uses, we could lose our competitive advantage and competition
we face would increase, reducing our potential revenuesand
adversely affecting our ability to attain
profitability.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>RisksRelated
to our Common Stock</u></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Themarket
price and volume of our common stock fluctuate significantly and
could result in substantial losses for individual
investors.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thestock
market from time to time experiences significant price and volume
fluctuations that are unrelated to the operating performanceof
particular companies. These broad market fluctuations may cause the
market price and volume of our common stock to decrease.In
addition, the market price and volume of our common stock is highly
volatile.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Factorsthat
may cause the market price and volume of our common stock to
decrease include:&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
results, termination, reduction, changes or delays in our or our
competitors clinical trials;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">fluctuations
in our results of operations, timing and announcements of our
bio-technological innovations or new products or those of our
competitors;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
concerning discussions that we may be in, or enter into, regarding
strategic alliances, partnerships, mergers, acquisitions, or
similar transactions;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
of FDA non-approval of our drug products, or delays in the FDA or
other foreign regulatory review process or actions;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
actions taken by regulatory agencies with respect to our drug
products, clinical trials, manufacturing processes or sales and
marketing activities;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">any
lawsuit involving us or our drug products;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">developments
with respect to our patents and proprietary rights;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements
of technological innovations or new products by our
competitors;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">public
concern as to the safety of products developed by us or
others;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
developments in the United States and in foreign
countries;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in stock market analyst recommendations regarding our common stock
or lack of analyst coverage;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">the
pharmaceutical industry conditions generally and general market
conditions;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
of our results of operations to meet the expectations of stock
market analysts and investors;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">sales
of our common stock by our executive officers, directors and five
percent stockholders or sales of substantial amounts of our common
stock;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in status of Nasdaq listing;</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">changes
in accounting principles; and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
of any of our key scientific or management personnel.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Themarket
for our common stock is illiquid. Our stockholders may not be able
to resell their shares at or above the purchase pricepaid by such
stockholders, or at all.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Ourcommon
stock is quoted on the NASDAQ Capital Market. The market for our
securities is illiquid. This illiquidity may be causedby a variety
of factors including:</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">lower
trading volume; and</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<!-- Field: Page; Sequence: 25; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.25in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">●</font></td>
<td style=
"text-align: justify; padding-right: 0.65pt; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">market
conditions.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereis
limited trading in our common stock and our security holders may
experience wide fluctuations in the market price of our
securities.Such price and volume fluctuations have particularly
affected the trading prices of equity securities of many
pharmaceutical andbiotechnology companies. These price and volume
fluctuations often appear to have been unrelated to the operating
performanceof the affected companies. These fluctuations may have
an extremely negative effect on the market price of our securities
andmay prevent a stockholder from obtaining a market price equal to
the purchase price such stockholder paid when the
stockholderattempts to sell our securities in the open market. In
these situations, the stockholder may be required either to sell
our securitiesat a market price which is lower than the purchase
price the stockholder paid, or to hold our securities for a longer
period oftime than planned. An inactive market may also impair our
ability to raise capital by selling shares of capital stock or to
recruitand retain managers with equity-based incentive
plans.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Asa
“smaller reporting company,” the Company may avail itself of
reduced disclosure requirements, which may make theCompany’s common
stock less attractive to investors.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Becausethe
market value of the Company’s common stock as of the end of its
most recently completed second fiscal quarter was lessthan $75
million, the Company is a “smaller reporting company” under
applicable SEC rules and regulations. As a “smallerreporting
company,” the Company has relied on exemptions from certain
disclosure requirements that are applicable to otherpublic
companies. The Company may continue to rely on such exemptions for
so long as the Company remains a “smaller reportingcompany.” These
exemptions include reduced financial disclosure, reduced disclosure
obligations regarding executive compensation,and not being required
to comply with the auditor attestation requirements of Section 404
of the Sarbanes-Oxley Act of 2002. TheCompany’s reliance on these
exemptions may result in the public finding the Company’s common
stock to be less attractiveand adversely impact the market price of
the Company’s common stock or the trading market
thereof.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Wewill
not pay cash dividends and investors may have to sell their shares
in order to realize their investment.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Wehave
not paid any cash dividends on our common stock and do not intend
to pay cash dividends in the foreseeable future. We intendto use
our cash for reinvestment in the development and marketing of our
products and services. As a result, investors may haveto sell their
shares of common stock to realize their investment.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Ourinternal
controls over financial reporting may not be effective which could
have a significant and adverse effect on our businessand
reputation.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Weare
subject to the requirements of Section 404 of the Sarbanes-Oxley
Act of 2002 and the rules and regulations of the SEC thereunder(
“Section 404”). Section 404 requires us to report on the design and
effectiveness of our internal controls over financialreporting. In
the past, our management has identified certain “material
weaknesses” in our internal controls overfinancial reporting which
we believe have been remediated. However, any failure to maintain
effective controls could result insignificant deficiencies or
material weaknesses, and cause us to fail to meet our periodic
reporting obligations, or result inmaterial misstatements in our
financial statements. We may also be required to incur costs to
improve our internal control systemand hire additional personnel.
This could negatively impact our results of
operations.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Compliancewith
changing regulation of corporate governance and public disclosure
may result in additional expenses and divert management’sattention
from operating our business, which could have a material adverse
effect on our business.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Therehave
been other changing laws, regulations and standards relating to
corporate governance and public disclosure in addition tothe
Sarbanes-Oxley Act, as well as new regulations promulgated by the
Commission and rules promulgated by the national
securitiesexchanges. These new or changed laws, regulations and
standards are subject to varying interpretations in many cases due
to theirlack of specificity, and as a result, their application in
practice may evolve over time as new guidance is provided by
regulatoryand governing bodies, which could result in continuing
uncertainty regarding compliance matters and higher costs
necessitatedby ongoing revisions to disclosure and governance
practices. As a result, our efforts to comply with evolving laws,
regulationsand standards are likely to continue to result in
increased general and administrative expenses and a diversion of
managementtime and attention from revenue-generating activities to
compliance activities. Our board members, Chief Executive Officer
andChief Financial Officer could face an increased risk of personal
liability in connection with the performance of their duties.As a
result, we may have difficulty attracting and retaining qualified
board members and executive officers, which could havea material
adverse effect on our business. If our efforts to comply with new
or changed laws, regulations and standards differfrom the
activities intended by regulatory or governing bodies, we may incur
additional expenses to comply with standards setby regulatory
authorities or governing bodies which would have a material adverse
effect on our business and results of operations.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delawarelaw
could discourage a change in control, or an acquisition of the
Company by a third party, even if the acquisition would befavorable
to stockholders.</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheDelaware
General Corporation Law contains provisions that may have the
effect of making more difficult or delaying attempts byothers to
obtain control of the Company, even when these attempts may be in
the best interests of stockholders. Delaware law imposesconditions
on certain business combination transactions with “interested
stockholders.” These provisions and othersthat could be adopted in
the future could deter unsolicited takeovers or delay or prevent
changes in our control or management,including transactions in
which stockholders might otherwise receive a premium for their
shares of common stock over then currentmarket prices. These
provisions may also limit the ability of stockholders to approve
transactions that they may deem to be intheir best
interests.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 26; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
</p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>OurBoard
of Directors has the authority to issue Serial Preferred Stock,
which could affect the rights of holders of our common stockand may
delay or prevent a takeover that could be in the best interests of
our stockholders.</b>&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">TheBoard
of Directors has the authority to issue up to 9,416,664 shares of
Serial Preferred Stock, $.0001 par value per share (the“Serial
Preferred Stock”) (after giving effect to the conversion and
cancellation of a previous issue of 5,583,336shares of Series B
Preferred), in one or more series and to fix the number of shares
constituting any such series, the votingpowers, designation,
preferences and relative participation, optional or other special
rights and qualifications, limitationsor restrictions thereof,
including the dividend rights and dividend rate, terms of
redemption (including sinking fund provisions),redemption price or
prices, conversion rights and liquidation preferences of the shares
constituting any series, without any furthervote or action by the
stockholders. 6,000,000 shares of the Serial Preferred Stock,
designated the Series B Preferred, have beenauthorized, 5,583,336
were issued and, as of the date of this filing, all such shares
have been converted and no Series B Preferredshares remain issued
and outstanding. The issuance of additional Serial Preferred Stock
could affect the rights of the holdersof Common Stock. For example,
such issuance could result in a class of securities outstanding
that would have preferential voting,dividend, and liquidation
rights over the Common Stock, and could (upon conversion or
otherwise) enjoy all of the rights appurtenantto the shares of
common stock. The authority possessed by the Board of Directors to
issue Serial Preferred Stock could potentiallybe used to discourage
attempts by others to obtain control of the Company through merger,
tender offer, proxy contest or otherwiseby making such attempts
more difficult or costly to achieve. The Board of Directors may
issue the Serial Preferred Stock withoutstockholder approval and
with voting and conversion rights which could adversely affect the
voting power of holders of commonstock. There are no agreements or
understandings for the issuance of Serial Preferred Stock and the
Board of Directors has nopresent intention to issue any Serial
Preferred Stock.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.75in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="ohrp10q033118a009"
id="ohrp10q033118a009"></a>Item 2.</b></font></td>
<td style=
"text-align: left; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Unregistered
Sales of Equity Securities and Use of Proceeds.</b></font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0in; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.75in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="ohrp10q033118a010"
id="ohrp10q033118a010"></a>Item 3.</b></font></td>
<td style=
"text-align: left; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Defaults
Upon Senior Securities.</b></font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font><font style="font-family: Times New Roman, Times, Serif">None.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.75in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><a name="ohrp10q033118a011"
id="ohrp10q033118a011"></a>Item 4.</font></td>
<td style=
"text-align: left; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine
Safety Disclosures.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Notapplicable.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.75in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><a name="ohrp10q033118a012"
id="ohrp10q033118a012"></a>Item 5.</font></td>
<td style=
"text-align: left; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
Information.</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font><font style="font-family: Times New Roman, Times, Serif">None.</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 0%; font-family: Times New Roman, Times, Serif">
</td>
<td style=
"width: 0.75in; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><a name="ohrp10q033118a013"
id="ohrp10q033118a013"></a>Item 6.</b></font></td>
<td style=
"text-align: left; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibits.</b></font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%">
<tr style="vertical-align: top">
<td style=
"width: 5%; text-align: left; border-bottom: Black 1pt solid">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit</font></td>
<td style="width: 7%">&nbsp;</td>
<td style="border-bottom: Black 1pt solid; width: 88%"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Number</font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style=
"width: 5%; text-align: left; font-family: Times New Roman, Times, Serif">
<a href="ex31-1.htm"><font style=
"font-family: Times New Roman, Times, Serif"><font style=
"font-size: 10pt">31.1</font></font></a></td>
<td>&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif"><font style=
"font-size: 10pt">Certification of Chief Executive Officer Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002</font></font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style=
"width: 5%; text-align: left; font-family: Times New Roman, Times, Serif">
<a href="ex31-2.htm"><font style=
"font-family: Times New Roman, Times, Serif"><font style=
"font-size: 10pt">31.2</font></font></a></td>
<td>&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif"><font style=
"font-size: 10pt">Certification of Chief Financial Officer Pursuant
to Section 302 of the Sarbanes-Oxley Act of 2002</font></font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif">
<a href="ex32-1.htm"><font style=
"font-family: Times New Roman, Times, Serif"><font style=
"font-size: 10pt">32.1</font></font></a></td>
<td>&nbsp;</td>
<td style=
"text-align: left; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif"><font style=
"font-size: 10pt">Certification of Chief Executive Officer Pursuant
to 18 U.S.C Section 1350, As Adopted Pursuant to Section 906 of the
Sarbanes Oxley Act of 2002</font></font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 5%; font-family: Times New Roman, Times, Serif">
<a href="ex32-2.htm"><font style=
"font-family: Times New Roman, Times, Serif"><font style=
"font-size: 10pt">32.2</font></font></a></td>
<td>&nbsp;</td>
<td style=
"text-align: left; font-family: Times New Roman, Times, Serif">
<font style=
"font-family: Times New Roman, Times, Serif"><font style=
"font-size: 10pt">Certification of Chief Financial Officer Pursuant
to 18 U.S.C Section 1350, As Adopted Pursuant to Section 906 of the
Sarbanes Oxley Act of 2002</font></font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style="width: 11%; border: Black 0pt solid"><font style=
"font-size: 10pt">101.INS</font></td>
<td style=
"border-top: Black 0pt solid; border-right: Black 0pt solid; border-bottom: Black 0pt solid">
&nbsp;</td>
<td style=
"border-top: Black 0pt solid; border-right: Black 0pt solid; border-bottom: Black 0pt solid">
<font style="font-size: 10pt">XBRL Instance Document</font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid; border-left: Black 0pt solid">
<font style="font-size: 10pt">101.SCH</font></td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
&nbsp;</td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
<font style="font-size: 10pt">XBRL Taxonomy Extension Schema
Document</font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid; border-left: Black 0pt solid">
<font style="font-size: 10pt">101.CAL</font></td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
&nbsp;</td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
<font style="font-size: 10pt">XBRL Taxonomy Extension Calculation
Linkbase Document</font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid; border-left: Black 0pt solid">
<font style="font-size: 10pt">101.DEF</font></td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
&nbsp;</td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
<font style="font-size: 10pt">XBRL Taxonomy Extension Definition
Linkbase Document</font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid; border-left: Black 0pt solid">
<font style="font-size: 10pt">101.LAB</font></td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
&nbsp;</td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
<font style="font-size: 10pt">XBRL Taxonomy Extension Label
Linkbase Document</font></td>
</tr>
<tr style=
"vertical-align: top; font-family: Times New Roman, Times, Serif">
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid; border-left: Black 0pt solid">
<font style="font-size: 10pt">101.PRE</font></td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
&nbsp;</td>
<td style=
"border-right: Black 0pt solid; border-bottom: Black 0pt solid">
<font style="font-size: 10pt">XBRL Taxonomy Extension Presentation
Linkbase Document</font></td>
</tr>
</table>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
</p>
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<!-- Field: Page; Sequence: 27; Value: 2 -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27
<!-- Field: /Sequence --></p>
</div>
<div style=
"page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
<p style="margin: 0pt"></p>
</div>
<!-- Field: /Page -->
<p style=
"margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<b>SIGNATURES</b></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in; text-align: justify">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuantto
the requirements of the Securities Exchange Act, the registrant has
duly caused this report to be signed on its behalf by
theundersigned, thereunto duly authorized.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:<font style="background-color: White">May
15, 2018</font></font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">OHRPHARMACEUTICAL,
INC.&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant)&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
</p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style=
"vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">
<td style=
"width: 3%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></td>
<td style=
"width: 47%; font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Dr. Jason S. Slakter</font></td>
<td style=
"width: 50%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">
<font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style=
"vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">
<td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
<td style="font-family: Times New Roman, Times, Serif">Dr. Jason
Slakter</td>
<td style="font-family: Times New Roman, Times, Serif">&nbsp;</td>
</tr>
<tr style=
"vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Executive Officer</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style=
"vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">(Principal Executive
Officer)</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<table cellpadding="0" cellspacing="0" style=
"border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style=
"vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">
<td style=
"width: 3%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">
<font style=
"font-family: Times New Roman, Times, Serif">By:</font></td>
<td style=
"width: 47%; font-family: Times New Roman, Times, Serif; border-bottom: Black 1pt solid">
<font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Sam Backenroth</font></td>
<td style=
"width: 50%; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">
<font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style=
"vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Sam
Backenroth</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style=
"vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
Financial Officer</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
<tr style=
"vertical-align: top; text-align: left; font-family: Times New Roman, Times, Serif">
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
Financial and Accounting Officer)</font></td>
<td style="font-family: Times New Roman, Times, Serif"><font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></td>
</tr>
</table>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
<font style=
"font-family: Times New Roman, Times, Serif">&nbsp;</font></p>
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
</p>
<!-- Field: Page; Sequence: 28; Options: Last -->
<div style=
"margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
<p style=
"margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28
<!-- Field: /Sequence --></p>
</div>
<!-- Field: /Page -->
<p style=
"font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: left; text-indent: 0">
</p>
</body>
</html>

